<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0102210484
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2015
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        DIOSTAR 80 mg film-coated tablet
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        VALSARTAN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        80
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        22.4
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Pharma International Co." />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Pharma International Co.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 513]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SAUDI ARABIAN DRUG STORE COMPANY
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Pharma International Co.
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C09DA03
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="margin-left:34.2pt; margin-right:3.95pt; text-align:left"><strong>Diostar</strong><strong>&reg; </strong>belongs to a class of medicines known as angiotensin II receptor antagonists )ARBs(, which help to control high blood pressure. Angiotensin II is a substance in the body that causes vessels to tighten, thus causing your blood pressure to increase. <strong>Diostar</strong><strong>&reg; </strong>works by blocking the effect of angiotensin II. As a result, blood vessels relax and blood pressure is lowered.</p><p style="text-align:left">&nbsp;</p><p style="margin-left:34.2pt; margin-right:0cm; text-align:left"><strong>Diostar</strong><strong>&reg; </strong>80mg and 160mg tablets can be used:</p><p style="margin-left:34.2pt; margin-right:0.4pt; text-align:left; text-indent:1.1pt"><!--[if !supportLists]-->- <!--[endif]-->To treat people after a recent heart attack )myocardial infarction(<strong>. </strong>&rdquo;Recent&ldquo; here means between 12 hours and 10 days.</p><p style="margin-left:34.2pt; margin-right:4.4pt; text-align:left; text-indent:1.1pt"><!--[if !supportLists]-->- <!--[endif]-->To treat symptomatic heart failure. <strong>Diostar</strong><strong>&reg; </strong>is used when a group of medicines called Angio- tensin Converting Enzyme )ACE( inhibitors )a medication to treat heart failure( cannot be used, or it may be used in addition to ACE inhibitors when beta blockers )another medication to treat heart failure( cannot be used.</p><p style="margin-left:34.2pt; margin-right:1.55pt; text-align:left">Heart failure symptoms include shortness of breath, and swelling of the feet and legs due to fluid build-up. It is caused when the heart muscle cannot pump blood strongly enough to supply all the blood needed throughout the body.</p><p style="text-align:left">&nbsp;</p><p style="margin-left:34.2pt; margin-right:0cm; text-align:left">In addition <strong>Diostar</strong><strong>&reg; </strong>80mg and 160mg tablets can be used:</p><p style="margin-left:34.2pt; margin-right:0.95pt; text-align:left; text-indent:1.1pt"><!--[if !supportLists]-->- <!--[endif]-->To treat high blood pressure. High blood pressure increases the workload on the heart and arter- ies. If not treated it can damage the blood vessels of the brain, heart, and kidneys, and may result in a stroke, heart failure, or kidney failure. High blood pressure increases the risk of heart attacks. Lowering your blood pressure to normal reduces the risk of developing these disorders.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="text-align:left">Do not take Diostar&reg; tablets</p><p style="margin-left:37.95pt; text-align:left"><!--[if !supportLists]-->- <!--[endif]-->If you are allergic )hypersensitive( to valsartan or any of the other ingredients of <strong>Diostar</strong><strong>&reg;</strong>.</p><p style="margin-left:34.2pt; text-align:left">)Listed in Section 6: Further information(</p><p style="margin-left:37.95pt; margin-right:0cm; text-align:left"><!--[if !supportLists]-->- <!--[endif]-->If you have severe liver disease.</p><p style="margin-left:34.2pt; margin-right:3.6pt; text-align:left; text-indent:1.1pt"><!--[if !supportLists]-->- <!--[endif]-->If you are more than 3 months pregnant )it is also better to avoid <strong>Diostar</strong><strong>&reg; </strong>in early pregnancy- see &rdquo;Pregnancy and breast-feeding&ldquo; section(.</p><p style="margin-left:37.4pt; text-align:left; text-indent:-2.3pt"><!--[if !supportLists]-->- <!--[endif]--><strong>Diostar</strong><strong>&reg; </strong>should not be administered with aliskiren in patients with diabetes mellitus or renal impairment.</p><p style="text-align:left">If any of these apply to you, speak to your doctor.</p><p style="text-align:left"><strong>&nbsp;</strong></p><p style="margin-left:34.2pt; text-align:left"><strong>You must be especially careful and talk to your doctor before taking Diostar</strong><strong>&reg; </strong><strong>if any of the following apply to you:</strong></p><p style="margin-left:37.95pt; text-align:left"><!--[if !supportLists]-->- <!--[endif]-->If you have liver disease.</p><p style="margin-left:37.95pt; text-align:left"><!--[if !supportLists]-->- <!--[endif]-->If you have severe kidney disease or if you are undergoing dialysis<strong>.</strong></p><p style="margin-left:37.95pt; margin-right:0cm; text-align:left"><!--[if !supportLists]-->- <!--[endif]-->If you are suffering from a narrowing of the kidney artery.</p><p style="margin-left:37.95pt; text-align:left"><!--[if !supportLists]-->- <!--[endif]-->If you have recently undergone kidney transplantation )received a new kidney(.</p><p style="margin-left:34.2pt; margin-right:9.1pt; text-align:left; text-indent:1.1pt"><!--[if !supportLists]-->- <!--[endif]-->If you are being treated after a heart attack or for heart failure. Your doctor may check your kidney function.</p><p style="margin-left:37.95pt; text-align:left"><!--[if !supportLists]-->- <!--[endif]-->If you have severe heart disease other than heart failure or heart attack.</p><p style="margin-left:34.2pt; margin-right:1.3pt; text-align:left; text-indent:1.1pt"><!--[if !supportLists]-->- <!--[endif]-->If you have ever experienced swelling of the tongue and face caused by an allergic reaction called angioedema when taking another drug )including ACE inhibitors(, tell your doctor. If these symptoms occur when you are taking <strong>Diostar</strong><strong>&reg;</strong>, stop taking <strong>Diostar</strong><strong>&reg; </strong>immediately and never take it again. )See section 4: &rdquo;Possible side effects&ldquo;(</p><p style="margin-left:34.2pt; margin-right:0.9pt; text-align:left; text-indent:1.1pt"><!--[if !supportLists]-->- <!--[endif]-->If you are taking medicines that increase the amount of potassium in your blood. These include potassium supplements or salt substitutes containing potassium, potassium-sparing medicines and heparin. It may be necessary to check the amount of potassium in your blood at regular intervals.</p><p style="margin-left:34.2pt; margin-right:0.7pt; text-align:left; text-indent:1.1pt"><!--[if !supportLists]-->- <!--[endif]-->If you suffer from aldosteronism. This is a disease in which your adrenal glands make too much of the hormone aldosterone. If this applies to you, the use of <strong>Diostar</strong><strong>&reg; </strong>is not recommended.</p><p style="margin-left:34.2pt; margin-right:0.55pt; text-align:left; text-indent:1.1pt"><!--[if !supportLists]-->- <!--[endif]-->If you have lost a lot of fluid )dehydration( caused by diarrhea, vomiting, or high doses of water pills )diuretics(.</p><p style="margin-left:37.85pt; text-align:left; text-indent:-2.6pt"><!--[if !supportLists]-->- <!--[endif]-->The use of <strong>Diostar</strong><strong>&reg; </strong>in children and adolescents below the age of 18 years is not recommended.</p><p style="margin-left:34.2pt; margin-right:1.95pt; text-align:left; text-indent:1.1pt"><!--[if !supportLists]-->- <!--[endif]-->You must tell your doctor if you think you are )or might become( pregnant. <strong>Diostar</strong><strong>&reg; </strong>is not recommended in early pregnancy, and must not be taken if you are more than 3 months pregnant, as it may cause serious harm to your baby if used at that stage )see pregnancy section(.</p><p style="text-align:left">&nbsp;</p><p style="text-align:left">Taking other medicines</p><p style="margin-left:34.2pt; margin-right:0.55pt; text-align:left">Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.</p><p style="text-align:left">&nbsp;</p><p style="margin-left:34.2pt; margin-right:6.95pt; text-align:left">The effect of the treatment can be influenced if <strong>Diostar</strong><strong>&reg; </strong>is taken together with certain other medicines. It may be necessary to change the dose, to take other precautions, or in some cases to stop taking one of the medicines. This applies to both prescription and non-prescription medicines, especially:</p><p style="text-align:left">&nbsp;</p><p style="margin-left:37.95pt; text-align:left"><!--[if !supportLists]-->- <!--[endif]--><strong>Other medicines that lower blood pressure</strong>, especially <strong>water pills </strong>)diuretics(.</p><p style="margin-left:35.3pt; text-align:left"><strong>- Aliskiren containing medicines </strong>)for treatment of high blood pressure(.</p><p style="margin-left:34.2pt; margin-right:4.55pt; text-align:left; text-indent:1.1pt"><!--[if !supportLists]-->- <!--[endif]--><strong>Medicines that increase the amount of potassium </strong>in your blood. These include potassium supplements or salt substitutes containing potassium, potassium-sparing medicines and heparin.</p><p style="margin-left:37.95pt; text-align:left"><!--[if !supportLists]-->- <!--[endif]--><strong>Certain type of pain killers </strong>called non-steroidal anti-inflammatory medicines <strong>)NSAIDs(</strong>.</p><p style="margin-left:34.2pt; margin-right:6.05pt; text-align:left; text-indent:1.1pt"><!--[if !supportLists]-->- <!--[endif]-->Some antibiotics )rifamycin group(, a drug used to protect against transplant rejection )ciclo- sporin( or an antiretroviral drug used to treat HIV/AIDS infection )ritonavir(. These drugs may increase the effect of <strong>Diostar</strong><strong>&reg;</strong>.</p><p style="margin-left:37.95pt; margin-right:0cm; text-align:left"><!--[if !supportLists]-->- <!--[endif]--><strong>Lithium</strong>, a medicine used to treat some types of psychiatric illness.</p><p style="text-align:left">&nbsp;</p><p style="text-align:left">In addition:</p><p style="margin-left:34.2pt; margin-right:3.85pt; text-align:left; text-indent:1.1pt"><!--[if !supportLists]-->- <!--[endif]-->If you are being <strong>treated after a heart attack, </strong>a combination with <strong>ACE inhibitors </strong>)a medica- tion to treat heart attack( is not recommended.</p><p style="margin-left:34.2pt; margin-right:1.9pt; text-align:left; text-indent:1.1pt"><!--[if !supportLists]-->- <!--[endif]-->If you are being <strong>treated for heart failure, </strong>a triple combination with <strong>ACE inhibitors and beta blockers </strong>)medications to treat heart failure( is not recommended<strong>.</strong></p><p style="text-align:left"><strong>&nbsp;</strong></p><p style="text-align:left">Taking Diostar&reg; tablets with food and drink</p><p style="margin-left:34.2pt; margin-right:0cm; text-align:left">You can take <strong>Diostar</strong><strong>&reg; </strong>tablets with or without food.</p><p style="text-align:left">&nbsp;</p><p style="text-align:left">Pregnancy and breast-feeding</p><p style="margin-left:34.2pt; text-align:left">Ask your doctor or pharmacist for advice before taking any medicine.</p><p style="text-align:left">&nbsp;</p><p style="margin-left:34.2pt; margin-right:2.75pt; text-align:left; text-indent:1.1pt"><!--[if !supportLists]-->- <!--[endif]--><strong>You </strong><strong>must tell your doctor if you think that you are )or might become( pregnant</strong>. Your doctor will normally advise you to stop taking <strong>Diostar</strong><strong>&reg; </strong>before you become pregnant or as soon as you know you are pregnant, and will advise you to take another medicine instead of <strong>Diostar</strong><strong>&reg;</strong>. <strong>Diostar</strong><strong>&reg; </strong>is not recommended in early pregnancy, and must not be taken when more than 3 months pregnant, as it may cause serious harm to your baby if it is used after the third month</p><p style="margin-left:34.2pt; margin-right:0cm; text-align:left">of pregnancy.</p><p style="text-align:left">&nbsp;</p><p style="margin-left:34.2pt; margin-right:1.05pt; text-align:left; text-indent:1.1pt"><!--[if !supportLists]-->- <!--[endif]--><strong>Tell </strong><strong>your doctor if you are breast-feeding or about to start breast-feeding. Diostar</strong><strong>&reg; </strong>is not recommended for mothers who are breast-feeding, and your doctor may choose another treatment for you if you wish to breast-feed, especially if your baby is newborn, or was born prematurely.</p><p style="text-align:left">&nbsp;</p><p style="text-align:left">Driving and using machines</p><p style="margin-left:34.2pt; text-align:left">Before you drive a vehicle, use tools or operate machines, or carry out other activities that require con- centration, make sure you know how <strong>Diostar</strong><strong>&reg; </strong>affects you. Like many other medicines used to treat high blood pressure, <strong>Diostar</strong><strong>&reg; </strong>may in rare cases cause dizziness and affect the ability to concentrate.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="margin-left:34.2pt; margin-right:217.45pt; text-align:left">Always take <strong>Diostar</strong><strong>&reg; </strong>tablets exactly as your doctor has told you. You should check with your doctor or pharmacist if you are not sure.</p><p style="text-align:left">&nbsp;</p><p style="margin-left:34.2pt; margin-right:209.45pt; text-align:left"><strong>After a recent heart attack: </strong>After a heart attack the treatment is generally started as early as after 12 hours, usually at a low dose of 20 mg twice daily. Your doctor will increase this dose gradually over several weeks to a maximum of 160 mg twice daily. The final dose depends on what you as an individual patient can tolerate.</p><p style="margin-left:34.2pt; margin-right:213.7pt; text-align:left"><strong>Diostar</strong><strong>&reg; </strong>can be given together with other treatment for heart attack, and your doctor will decide which treatment is suitable for you.</p><p style="text-align:left">&nbsp;</p><p style="margin-left:19.6pt; margin-right:225.55pt; text-align:left" dir="rtl"><strong>Heart failure: </strong>Treatment starts generally with 40 mg twice daily. Your doctor will increase the dose gradually over several weeks to a maximum of 160 mg twice daily. The final dose depends on what you as an individual patient can tolerate.</p><p style="margin-left:19.6pt; margin-right:225.55pt; text-align:left" dir="rtl"><strong>Diostar</strong><strong>&reg; </strong>can be given together with other treatments for heart failure, and your doctor will decide which treatment is suitable for you.</p><p style="text-align:left" dir="rtl">&nbsp;</p><p style="margin-left:18.45pt; margin-right:225.55pt; text-align:left" dir="rtl"><strong>High blood pressure: </strong>The usual dose is 80 mg daily. In some cases your doctor may prescribe higher doses )e.g. 160 mg or 320 mg(. He may also combine <strong>Diostar</strong><strong>&reg; </strong>with an additional medicine</p><p style="margin-right:225.55pt; text-align:left" dir="rtl">)e.g. a diuretic</p><p style="margin-left:42.45pt; margin-right:225.55pt; text-align:left" dir="rtl">You can take <strong>Diostar</strong><strong>&reg; </strong>with or without food. Swallow <strong>Diostar</strong><strong>&reg; </strong>with a glass of water. Take <strong>Diostar</strong><strong>&reg; </strong>at about the same time each day</p><p style="text-align:left">&nbsp;</p><p style="text-align:left">If you take more Diostar&reg; than you should</p><p style="margin-left:12.3pt; margin-right:19.6pt; text-align:left">If you experience severe dizziness and/or fainting, lie down and contact your doctor immediately. If you have accidentally taken too many tablets, contact your doctor or pharmacist or hospital emergency department immediately. Always take any tablets left over with you, also the box and leaflet as this will allow easier identification of the tablets.</p><p style="text-align:left">&nbsp;</p><p style="text-align:left">If you forget to take Diostar&reg;</p><p style="margin-left:12.3pt; text-align:left">Do not take a double dose to make up for a forgotten dose.</p><p style="margin-left:12.3pt; margin-right:23.6pt; text-align:left">If you forget to take a dose, take it as soon as you remember. However, if it is almost time for your next dose, skip the dose you missed.</p><p style="text-align:left">&nbsp;</p><p style="text-align:left">If you stop taking Diostar&reg;</p><p style="margin-left:12.3pt; margin-right:23.6pt; text-align:left">Stopping your treatment with <strong>Diostar</strong><strong>&reg; </strong>may cause your disease to get worse. Do not stop taking your medicine unless your doctor tells you to.</p><p style="margin-left:12.3pt; text-align:left">If you have further questions on the use of this product, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="margin-left:12.3pt; margin-right:31.25pt; text-align:left">Like all medicines, this medicine can cause side effects, although not everybody gets them. These side effects may occur with certain frequencies, which are defined as follows:</p><p style="margin-left:15.95pt; text-align:left; text-indent:-2.6pt"><!--[if !supportLists]-->- <!--[endif]-->Very common: affects more than 1 user in 10</p><p style="text-align:left"><!--[if !supportLists]-->- <!--[endif]-->Common: affects 1 to 10 users in 100</p><p style="text-align:left"><!--[if !supportLists]-->- <!--[endif]-->Uncommon: affects 1 to 10 users in 1,000</p><p style="text-align:left"><!--[if !supportLists]-->- <!--[endif]-->Rare: affects 1 to 10 users in 10,000</p><p style="margin-left:15.95pt; text-align:left; text-indent:-2.6pt"><!--[if !supportLists]-->- <!--[endif]-->Very rare: affects less than 1 user in 10,000</p><p style="text-align:left"><!--[if !supportLists]-->- <!--[endif]-->Not known: frequency cannot be estimated from the available data.</p><p style="text-align:left">&nbsp;</p><p style="text-align:left">Some symptoms need immediate medical attention:</p><p style="margin-left:12.3pt; text-align:left">You may experience symptoms of angioedema, such as</p><p style="text-align:left"><!--[if !supportLists]-->- <!--[endif]-->Swollen face, tongue or throat</p><p style="text-align:left"><!--[if !supportLists]-->- <!--[endif]-->Difficulty in swallowing</p><p style="text-align:left"><!--[if !supportLists]-->- <!--[endif]-->Hives and difficulties in breathing</p><p style="text-align:left">If you get any of these symptoms, stop taking Diostar&reg; and contact your doctor straight away )see also section 2 &ldquo;Take special care with Diostar&reg;&ldquo;(.</p><p style="text-align:left"><strong>&nbsp;</strong></p><p style="margin-left:12.3pt; text-align:left"><strong>Other side effects include:</strong></p><p style="margin-left:12.3pt; margin-right:0cm; text-align:left"><strong>Common</strong>:</p><p style="text-align:left"><!--[if !supportLists]-->- <!--[endif]-->Dizziness, postural dizziness</p><p style="text-align:left"><!--[if !supportLists]-->- <!--[endif]-->Low blood pressure with symptoms such as dizziness</p><p style="text-align:left"><!--[if !supportLists]-->- <!--[endif]-->Decreased kidney function )signs of renal impairment(</p><p style="text-align:left">&nbsp;</p><p style="text-align:left">Uncommon<em>:</em></p><p style="margin-left:12.3pt; margin-right:29pt; text-align:left; text-indent:1.1pt"><!--[if !supportLists]-->-<!--[endif]-->Allergic reaction with symptoms such as rash, itching, dizziness, swelling of face or lips or tongue or throat, difficulty breathing or swallowing )signs of angioedema(</p><p style="text-align:left"><!--[if !supportLists]-->- <!--[endif]-->Sudden loss of consciousness</p><p style="text-align:left"><!--[if !supportLists]-->- <!--[endif]-->Spinning sensation</p><p style="text-align:left"><!--[if !supportLists]-->- <!--[endif]-->Severely decreased kidney function )signs of acute renal failure(</p><p style="text-align:left"><!--[if !supportLists]-->- <!--[endif]-->Muscle spasms, abnormal heart rhythm )signs of hyperkalemia(</p><p style="text-align:left"><!--[if !supportLists]-->- <!--[endif]-->Breathlessness, difficulty breathing when lying down, swelling of the feet or legs )signs of cardiac failure(</p><p style="text-align:left"><!--[if !supportLists]-->- <!--[endif]-->Headache</p><p style="text-align:left"><!--[if !supportLists]-->- <!--[endif]-->Cough</p><p style="margin-left:15.8pt; margin-right:0cm; text-align:left; text-indent:-2.45pt"><!--[if !supportLists]-->- <!--[endif]-->Abdominal pain</p><p style="text-align:left"><!--[if !supportLists]-->- <!--[endif]-->Nausea</p><p style="text-align:left"><!--[if !supportLists]-->- <!--[endif]-->Diarrhea</p><p style="margin-left:15.95pt; text-align:left; text-indent:-2.6pt"><!--[if !supportLists]-->- <!--[endif]-->Tiredness</p><p style="margin-left:15.95pt; margin-right:0cm; text-align:left; text-indent:-2.6pt"><!--[if !supportLists]-->- <!--[endif]-->Weakness</p><p style="text-align:left">&nbsp;</p><p style="text-align:left">Not known:</p><p style="margin-left:12.3pt; margin-right:21.2pt; text-align:left; text-indent:1.1pt"><!--[if !supportLists]-->- <!--[endif]-->Rash, itching, together with some of the following signs or symptoms: fever, joint pain, muscle pain, swollen lymph nodes and/or flu-like symptoms )signs of serum sickness(</p><p style="text-align:left"><!--[if !supportLists]-->- <!--[endif]-->Purple-red spots, fever, itching )signs of inflammation of blood vessels also called vasculitis(</p><p style="text-align:left"><!--[if !supportLists]-->- <!--[endif]-->Unusual bleeding or bruising )signs of thrombocytopenia(</p><p style="text-align:left"><!--[if !supportLists]-->- <!--[endif]-->Muscle pain )myalgia(</p><p style="margin-left:12.3pt; margin-right:20.05pt; text-align:left; text-indent:1.1pt"><!--[if !supportLists]-->- <!--[endif]-->Fever, sore throat or mouth ulcers due to infections )symptoms of low level of white blood cells also called neutropenia(</p><p style="text-align:left"><!--[if !supportLists]-->- <!--[endif]-->Decrease of level of hemoglobin and decrease of the percentage of red blood cells in the blood</p><p style="margin-left:12.3pt; margin-right:0cm; text-align:left">)which can, in severe cases, lead to anemia(</p><p style="margin-left:12.3pt; margin-right:22.55pt; text-align:left; text-indent:1.1pt"><!--[if !supportLists]-->- <!--[endif]-->Increase of level of potassium in the blood )which can, in severe cases, trigger muscle spasms, abnormal heart rhythm(</p><p style="margin-left:12.3pt; margin-right:25.65pt; text-align:left; text-indent:1.1pt"><!--[if !supportLists]-->- <!--[endif]-->Elevation of liver function values )which can indicate liver damage( including an increase of bilirubin in the blood )which can, in severe cases, trigger yellow skin and eyes(</p><p style="margin-left:12.3pt; margin-right:26.4pt; text-align:left; text-indent:1.1pt"><!--[if !supportLists]-->- <!--[endif]-->Increase of level of blood urea nitrogen and increase of level of serum creatinine )which can indicate abnormal kidney function(</p><p style="margin-left:12.3pt; margin-right:19.2pt; text-align:left; text-indent:1.1pt"><!--[if !supportLists]-->- <!--[endif]-->Low level of sodium in the blood )which can trigger tiredness, confusion, muscle twitching and/ or convulsions in severe cases(</p><p style="text-align:left">&nbsp;</p><p style="margin-left:12.3pt; margin-right:14.35pt; text-align:left">The frequency of some side effects may vary depending on your condition. For example, side ef- fects such as dizziness, and decreased kidney function, were seen less frequently in patients treated with high blood pressure than in patients treated for heart failure or after a recent heart attack.</p><p style="text-align:left">&nbsp;</p><p style="text-align:left">If any of the side effects gets serious or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="margin-left:12.3pt; margin-right:0cm; text-align:left">Keep out of the reach and sight of children.</p><p style="margin-left:12.3pt; margin-right:33.2pt; text-align:left">Do not use this medicine after the expiry date which is stated on the blister and the carton. The expiry date refers to the last day of that month.</p><p style="margin-left:12.3pt; margin-right:0cm; text-align:left"><strong>Diostar</strong><strong>&reg; </strong><strong>tablets: </strong>Store below 25&deg;C.</p><p style="text-align:left">Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="margin-left:12.3pt; margin-right:0cm; text-align:left">The active substance is Valsartan.</p><p style="margin-left:12.3pt; margin-right:26.35pt; text-align:left">The other ingredients are microcrystalline cellulose, croscarmellose sodium, Povidone K, col- loidal silicon dioxide, magnesium stearate, Opadry OY-L White, FD&amp;C red.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Diostar® 80mg F/C tablets: are light pink, round, engraved with PhI on one face, and break line on the other Packed in Alu/Alu blisters, intended for oral use.

Pack size: 30 tablets

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="margin-left:12.3pt; margin-right:138.95pt; text-align:left">Pharma International Company Amman - Jordan</p><p style="margin-left:12.3pt; margin-right:0cm; text-align:left">Tel: 00962-6-5158890 / 5157893</p><p style="margin-left:12.3pt; margin-right:0cm; text-align:left">Fax: 00962-6-5154753</p><p style="margin-left:12.3pt; margin-right:0cm; text-align:left">Email: marketing@pic-jo.com</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in 12/2014
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p style="margin-left:0px; margin-right:0px" dir="rtl">ديوستار&nbsp;ينتمي&nbsp;إلى&nbsp;مجموعة&nbsp;من&nbsp;الأدوية&nbsp;تعرف&nbsp;بإسم&nbsp;مضادات&nbsp;مستقبلات&nbsp;الأنجيوتنسين(ARBsII)</p><p style="margin-left:0px; margin-right:0px">&nbsp;والتي&nbsp;تساعد على&nbsp;السيطرة&nbsp;على&nbsp;ارتفاع&nbsp;ضغط&nbsp;الدم.&nbsp;أنجيوتنسين&nbsp;II&nbsp;هي&nbsp;عبارة&nbsp;عن&nbsp;مادة&nbsp;في&nbsp;الجسم&nbsp;تسبب&nbsp;تضييق&nbsp;في&nbsp;الأوعية&nbsp;الدموية،</p><p style="margin-left:0px; margin-right:0px" dir="rtl">مما&nbsp;يؤدي&nbsp;إلى&nbsp;ارتفاع&nbsp;ضغط&nbsp;الدم.&nbsp;دیوستاره&nbsp;يعمل&nbsp;عن&nbsp;طريق&nbsp;منع&nbsp;تأثير&nbsp;أنجيوتنسين&nbsp;II&nbsp;ونتيجة&nbsp;لذلك،&nbsp;تسترخي&nbsp;الأوعية</p><p style="margin-left:0px; margin-right:0px" dir="rtl">الدموية&nbsp;وينخفض&nbsp;ضغط&nbsp;الدم</p><p style="margin-left:0px; margin-right:0px" dir="rtl">يمكن&nbsp;استخدام&nbsp;أقراص&nbsp;ديوستار&nbsp;80&nbsp;ملغم&nbsp;و&nbsp;160&nbsp;ملغم&nbsp;لما&nbsp;يلي:</p><p style="margin-left:0px; margin-right:0px" dir="rtl">-&nbsp;لعلاج&nbsp;الناس&nbsp;بعد&nbsp;اصابتهم&nbsp;مؤخرا&nbsp;بأزمة&nbsp;قلبية&nbsp;(احتشاء&nbsp;عضلة&nbsp;القلب).&nbsp;مؤخرا،&nbsp;تعني&nbsp;هنا&nbsp;بين&nbsp;12&nbsp;ساعة&nbsp;و&nbsp;10&nbsp;أيام.</p><p style="margin-left:0px; margin-right:0px" dir="rtl">-&nbsp;لعلاج&nbsp;أعراض&nbsp;قصور&nbsp;القلب.&nbsp;يستخدم&nbsp;ديوستار&nbsp;عندما&nbsp;لا&nbsp;يمكن&nbsp;استخدام&nbsp;مجموعة&nbsp;من&nbsp;الأدوية&nbsp;تسمى&nbsp;مثبطات&nbsp;الإنزيم</p><p style="margin-left:0px; margin-right:0px" dir="rtl">المحول&nbsp;للأنجيوتنسين&nbsp;(ACE) (دواء&nbsp;لعلاج&nbsp;قصور&nbsp;القلب)،&nbsp;أو&nbsp;يمكن&nbsp;استخدامها&nbsp;بالإضافة&nbsp;إلى&nbsp;مثبطات&nbsp;الإنزيم&nbsp;المحول</p><p style="margin-left:0px; margin-right:0px" dir="rtl">للأنجيوتنسين&nbsp;ACE&nbsp;عندما&nbsp;لا&nbsp;يمكن&nbsp;استخدام&nbsp;حاصرات&nbsp;بيتا&nbsp;(دواء&nbsp;آخر&nbsp;لعلاج&nbsp;قصور&nbsp;القلب).</p><p style="margin-left:0px; margin-right:0px" dir="rtl">أعراض&nbsp;قصور&nbsp;القلب&nbsp;تشمل&nbsp;الضيق&nbsp;في&nbsp;التنفس،&nbsp;وتورم&nbsp;في&nbsp;القدمين&nbsp;والساقين&nbsp;نتيجة&nbsp;لتراكم&nbsp;السوائل.&nbsp;يحدث&nbsp;ذلك&nbsp;عندما</p><p style="margin-left:0px; margin-right:0px" dir="rtl">تعجز&nbsp;عضلة&nbsp;القلب&nbsp;عن&nbsp;ضخ&nbsp;الدم&nbsp;بقوة&nbsp;كافية&nbsp;لتزويد&nbsp;كل&nbsp;الدم&nbsp;اللازم&nbsp;في&nbsp;جميع</p><p style="margin-left:0px; margin-right:0px" dir="rtl">بالإضافة&nbsp;إلى&nbsp;ذلك</p><p style="margin-left:0px; margin-right:0px" dir="rtl">يمكن&nbsp;استخدام&nbsp;أقراص&nbsp;ديوستار&nbsp;80&nbsp;ملغم&nbsp;و&nbsp;160&nbsp;ملغم&nbsp;لما يلي:</p><p style="margin-left:0px; margin-right:0px">&nbsp;</p><p style="margin-left:0px; margin-right:0px" dir="rtl">-&nbsp;لعلاج&nbsp;ارتفاع&nbsp;ضغط&nbsp;الدم.&nbsp;ارتفاع&nbsp;ضغط&nbsp;الدم&nbsp;يزيد&nbsp;من&nbsp;عبء&nbsp;العمل&nbsp;على&nbsp;القلب&nbsp;والشرايين.&nbsp;إذا&nbsp;لم&nbsp;يعالج&nbsp;فقد&nbsp;يتلف&nbsp;الأوعية</p><p style="margin-left:0px; margin-right:0px" dir="rtl">الدموية&nbsp;في&nbsp;الدماغ،&nbsp;القلب،&nbsp;والكلى،&nbsp;ويمكن&nbsp;أن&nbsp;يؤدي&nbsp;إلى&nbsp;السكتة&nbsp;الدماغية،&nbsp;فشل&nbsp;القلب،&nbsp;أو&nbsp;الفشل&nbsp;الكلوي.&nbsp;ارتفاع&nbsp;ضغط&nbsp;الدم</p><p style="margin-left:0px; margin-right:0px" dir="rtl">يزيد&nbsp;من&nbsp;مخاطر&nbsp;الإصابة&nbsp;بأزمات&nbsp;قلبية.&nbsp;خفض&nbsp;ضغط&nbsp;الدم&nbsp;إلى&nbsp;وضعه&nbsp;الطبيعي&nbsp;يقلل&nbsp;من&nbsp;خطر&nbsp;الاصابة&nbsp;بهذه&nbsp;الاضطرابات.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p style="margin-left:0px; margin-right:0px" dir="rtl">لا&nbsp;تأخذ&nbsp;ديوستار&nbsp;أقراص</p><p style="margin-left:0px; margin-right:0px" dir="rtl">-&nbsp;إذا&nbsp;كنت&nbsp;تعاني&nbsp;من&nbsp;حساسية&nbsp;(حساسية&nbsp;مفرطة&nbsp;لفالسارتان&nbsp;أو&nbsp;أي&nbsp;من&nbsp;المكونات&nbsp;الأخرى&nbsp;ل&nbsp;دیوستاره&nbsp;(المذكورة&nbsp;في</p><p style="margin-left:0px; margin-right:0px" dir="rtl">البند&nbsp;6:&nbsp;للمزيد&nbsp;من&nbsp;المعلومات).</p><p style="margin-left:0px; margin-right:0px" dir="rtl">-&nbsp;إذا&nbsp;كنت&nbsp;تعاني&nbsp;من&nbsp;مرض&nbsp;حاد&nbsp;في&nbsp;الكبد.</p><p style="margin-left:0px; margin-right:0px" dir="rtl">-&nbsp;إذا&nbsp;كنت&nbsp;حامل&nbsp;أكثر&nbsp;من&nbsp;3&nbsp;أشهر&nbsp;من&nbsp;الأفضل&nbsp;أيضا&nbsp;تجنب&nbsp;ديوستاره&nbsp;في&nbsp;مراحل&nbsp;الحمل&nbsp;المبكرة.&nbsp;انظر&nbsp;بند&nbsp;&rsquo;&rsquo;الحمل</p><p style="margin-left:0px; margin-right:0px" dir="rtl">والرضاعة&nbsp;الطبيعية)</p><p style="margin-left:0px; margin-right:0px" dir="rtl">-&nbsp;لا&nbsp;ينبغي&nbsp;استخدام&nbsp;ديوستار&nbsp;مع&nbsp;أليسكيرين&nbsp;للمرضى&nbsp;الذين&nbsp;يعانون&nbsp;من&nbsp;مرض&nbsp;السكري&nbsp;أو&nbsp;الفشل&nbsp;الكلوي.</p><p style="margin-left:0px; margin-right:0px" dir="rtl">إذا&nbsp;كانت&nbsp;أي&nbsp;من&nbsp;هذه&nbsp;الحالات&nbsp;تنطبق&nbsp;عليك،&nbsp;راجع&nbsp;طبيبك.</p><p style="margin-left:0px; margin-right:0px" dir="rtl">يجب&nbsp;أن&nbsp;تكون&nbsp;حذرة&nbsp;بصورة&nbsp;خاصة&nbsp;وتتحدث&nbsp;إلى&nbsp;طبيبك&nbsp;قبل&nbsp;استخدام&nbsp;ديوستار&nbsp;إذا&nbsp;كان&nbsp;أي&nbsp;مما&nbsp;يلي&nbsp;ينطبق&nbsp;عليك:</p><p style="margin-left:0px; margin-right:0px" dir="rtl">-&nbsp;إذا&nbsp;كنت&nbsp;تعاني&nbsp;من&nbsp;مرض&nbsp;في&nbsp;الكبد.</p><p style="margin-left:0px; margin-right:0px" dir="rtl">-&nbsp;إذا&nbsp;كانت&nbsp;تعاني&nbsp;من&nbsp;مرض&nbsp;حاد&nbsp;في&nbsp;الكلى&nbsp;أو&nbsp;كنت&nbsp;تخضع&nbsp;لغسيل&nbsp;الكلى.</p><p style="margin-left:0px; margin-right:0px" dir="rtl">-&nbsp;إذا&nbsp;كنت&nbsp;تعاني&nbsp;من&nbsp;تضيق&nbsp;في&nbsp;الشريان&nbsp;الكلوي</p><p style="margin-left:0px; margin-right:0px" dir="rtl">-&nbsp;إذا&nbsp;كنت&nbsp;قد&nbsp;خضعت&nbsp;مؤخرا&nbsp;لزراعة&nbsp;الكلى&nbsp;(الحصول&nbsp;على&nbsp;كلية&nbsp;جديدة).</p><p style="margin-left:0px; margin-right:0px" dir="rtl">-&nbsp;إذا&nbsp;كنت&nbsp;تخضع&nbsp;للعلاج&nbsp;بعد&nbsp;الإصابة&nbsp;بأزمة&nbsp;قلبية&nbsp;أو&nbsp;قصور&nbsp;القلب.&nbsp;طبيبك&nbsp;قد&nbsp;يقوم&nbsp;بفحص&nbsp;وظائف&nbsp;الكلى&nbsp;لديك.</p><p style="margin-left:0px; margin-right:0px" dir="rtl">-&nbsp;إذا&nbsp;كنت&nbsp;تعاني&nbsp;من&nbsp;أمراض&nbsp;خطيرة&nbsp;أخرى&nbsp;في&nbsp;القلب&nbsp;بخلاف&nbsp;قصور&nbsp;القلب&nbsp;أو&nbsp;الأزمة&nbsp;القلبية.</p><p style="margin-left:0px; margin-right:0px" dir="rtl">-&nbsp;أخبر&nbsp;طبيبك&nbsp;إذا&nbsp;عانيت&nbsp;في&nbsp;أي&nbsp;وقت&nbsp;مضى&nbsp;من&nbsp;تورم&nbsp;اللسان&nbsp;والوجه&nbsp;الناجم&nbsp;عن&nbsp;رد&nbsp;فعل&nbsp;تحسسي&nbsp;يعرف&nbsp;بالوذمة</p><p style="margin-left:0px; margin-right:0px" dir="rtl">الوعائية&nbsp;عند&nbsp;استخدام&nbsp;دواء&nbsp;آخر&nbsp;(بما&nbsp;في&nbsp;ذلك&nbsp;مثبطات&nbsp;الإنزيم&nbsp;المحول&nbsp;للأنجيوتنسين&nbsp;ACE).&nbsp;في&nbsp;حالة&nbsp;حدوث&nbsp;هذه</p><p style="margin-left:0px; margin-right:0px" dir="rtl">الأعراض&nbsp;عند&nbsp;استخدام&nbsp;دیوستاره،&nbsp;توقف&nbsp;عن&nbsp;تناول&nbsp;دیوستاره&nbsp;فورا&nbsp;ولا&nbsp;تتناوله&nbsp;مرة&nbsp;أخرى&nbsp;أبدا. (انظر&nbsp;البند&nbsp;4:&nbsp;الآثار</p><p style="margin-left:0px; margin-right:0px" dir="rtl">الجانبية&nbsp;المحتملة)</p><p style="margin-left:0px; margin-right:0px" dir="rtl">-&nbsp;إذا&nbsp;كنت&nbsp;تستخدم&nbsp;الأدوية&nbsp;التي&nbsp;تزيد&nbsp;من&nbsp;كمية&nbsp;البوتاسيوم&nbsp;في&nbsp;الدم.&nbsp;وتشمل&nbsp;هذه&nbsp;البوتاسيوم&nbsp;كمكملات&nbsp;غذائية&nbsp;أو&nbsp;بدائل</p><p style="margin-left:0px; margin-right:0px" dir="rtl">الملح&nbsp;المحتوية&nbsp;على&nbsp;البوتاسيوم،&nbsp;الأدوية&nbsp;الحافظة&nbsp;للبوتاسيوم&nbsp;والهيبارين.&nbsp;قد&nbsp;يكون&nbsp;من&nbsp;الضروري&nbsp;التحقق&nbsp;من&nbsp;كمية</p><p style="margin-left:0px; margin-right:0px" dir="rtl">البوتاسيوم&nbsp;في&nbsp;الدم&nbsp;على&nbsp;فترات&nbsp;منتظمة</p><p style="margin-left:0px; margin-right:0px" dir="rtl">-&nbsp;إذا&nbsp;كنت&nbsp;تعاني&nbsp;من&nbsp;ألدوستيرونية.&nbsp;و&nbsp;هو&nbsp;مرض&nbsp;تقوم&nbsp;به&nbsp;الغدد&nbsp;الكظرية&nbsp;بتصنيع&nbsp;الكثير&nbsp;من&nbsp;هرمون&nbsp;الألدوستيرون.&nbsp;إذا&nbsp;انطبق&nbsp;عليك&nbsp;ذلك،&nbsp;لاتستخدم&nbsp;دیوستار&nbsp;*</p><p style="margin-left:0px; margin-right:0px" dir="rtl">-&nbsp;إذا&nbsp;فقدت&nbsp;الكثير&nbsp;من&nbsp;السوائل&nbsp;(الجفاف)&nbsp;الناجمة&nbsp;عن&nbsp;الإسهال،&nbsp;القيء،&nbsp;أو&nbsp;جرعات&nbsp;عالية&nbsp;من&nbsp;حبوب&nbsp;الماء&nbsp;(مدرات&nbsp;البول)</p><p style="margin-left:0px; margin-right:0px" dir="rtl">-&nbsp;لا&nbsp;ينصح&nbsp;باستخدام&nbsp;ديوستار&nbsp;للأطفال&nbsp;والمراهقين&nbsp;دون&nbsp;سن&nbsp;18&nbsp;عام.</p><p style="margin-left:0px; margin-right:0px" dir="rtl">-&nbsp;عليك&nbsp;إخبار&nbsp;الطبيب&nbsp;إذا&nbsp;كنت&nbsp;(أو&nbsp;قد&nbsp;تصبحين)&nbsp;حامل.&nbsp;لا&nbsp;ينصح&nbsp;باستخدام&nbsp;دیوستاره&nbsp;في&nbsp;مرحلة&nbsp;مبكرة&nbsp;من&nbsp;الحمل،&nbsp;ولا</p><p style="margin-left:0px; margin-right:0px" dir="rtl">يستخدم&nbsp;نهائيا&nbsp;إذا&nbsp;كنت&nbsp;حامل&nbsp;أكثر&nbsp;من&nbsp;3&nbsp;أشهر،&nbsp;لأنه&nbsp;قد&nbsp;يسبب&nbsp;ضرر&nbsp;جسيم&nbsp;لطفلك&nbsp;إذا&nbsp;استخدمتيه&nbsp;في&nbsp;تلك&nbsp;المرحلة&nbsp;(انظر</p><p style="margin-left:0px; margin-right:0px" dir="rtl">بند&nbsp;الحمل&nbsp;والرضاعة&nbsp;الطبيعية)</p><p style="margin-left:0px; margin-right:0px" dir="rtl">تناول&nbsp;أدوية&nbsp;أخرى</p><p style="margin-left:0px; margin-right:0px" dir="rtl">يرجى&nbsp;إخبار&nbsp;الطبيب&nbsp;أو&nbsp;الصيدلي&nbsp;إذا&nbsp;كنت&nbsp;تستخدم&nbsp;أو&nbsp;استخدمت&nbsp;مؤخرا&nbsp;أي&nbsp;أدوية&nbsp;أخرى،&nbsp;بما&nbsp;في&nbsp;ذلك&nbsp;الأدوية&nbsp;التي&nbsp;تم</p><p style="margin-left:0px; margin-right:0px" dir="rtl">الحصول&nbsp;عليها&nbsp;دون&nbsp;وصفة&nbsp;طبية</p><p style="margin-left:0px; margin-right:0px" dir="rtl">قد&nbsp;يتأثر&nbsp;سير&nbsp;العلاج&nbsp;إذا&nbsp;تم&nbsp;استخدام&nbsp;ديوستار&nbsp;بالتزامن&nbsp;مع&nbsp;بعض&nbsp;الأدوية&nbsp;الأخرى.&nbsp;قد&nbsp;يكون&nbsp;من&nbsp;الضروري&nbsp;تغيير</p><p style="margin-left:0px; margin-right:0px" dir="rtl">الجرعة،&nbsp;أو&nbsp;اتخاذ&nbsp;احتياطات&nbsp;أخرى،&nbsp;أو&nbsp;في&nbsp;بعض&nbsp;الحالات&nbsp;التوقف&nbsp;عن&nbsp;استخدام&nbsp;واحد&nbsp;من&nbsp;الأدوية.&nbsp;وهذا&nbsp;ينطبق&nbsp;على</p><p style="margin-left:0px; margin-right:0px" dir="rtl">الأدوية&nbsp;التي&nbsp;يتم&nbsp;الحصول&nbsp;عليها&nbsp;بوصفة&nbsp;طبية&nbsp;أو&nbsp;غير&nbsp;وصفة&nbsp;طبية،&nbsp;وخاصة</p><p style="margin-left:0px; margin-right:0px" dir="rtl">-&nbsp;الأدوية&nbsp;الأخرى&nbsp;التي&nbsp;تخفض&nbsp;ضغط&nbsp;الدم،&nbsp;خاصة&nbsp;حبوب&nbsp;الماء&nbsp;(مدرات&nbsp;البول)</p><p style="margin-left:0px; margin-right:0px" dir="rtl">-&nbsp;الأدوية&nbsp;المحتوية&nbsp;على&nbsp;المادة&nbsp;الفعالة&nbsp;أليسكرين&nbsp;(لعلاج&nbsp;ارتفاع&nbsp;ضغط&nbsp;الدم)</p><p style="margin-left:0px; margin-right:0px" dir="rtl">-&nbsp;الأدوية&nbsp;التي&nbsp;تزيد&nbsp;من&nbsp;كمية&nbsp;البوتاسيوم&nbsp;في&nbsp;الدم.&nbsp;وتشمل&nbsp;هذه&nbsp;البوتاسيوم&nbsp;كمكملات&nbsp;غذائية&nbsp;أو&nbsp;بدائل&nbsp;الملح&nbsp;المحتوية&nbsp;على</p><p style="margin-left:0px; margin-right:0px" dir="rtl">البوتاسيوم،&nbsp;الأدوية&nbsp;الحافظة&nbsp;للبوتاسيوم&nbsp;والهيبارين</p><p style="margin-left:0px; margin-right:0px" dir="rtl">-&nbsp;أنواع&nbsp;معينة&nbsp;من&nbsp;المسكنات&nbsp;تسمى&nbsp;الأدوية&nbsp;المضادة&nbsp;للالتهابات&nbsp;غير&nbsp;الستيرويدية&nbsp;(NSAIDs)</p><p style="margin-left:0px; margin-right:0px" dir="rtl">-&nbsp;بعض&nbsp;المضادات&nbsp;الحيوية&nbsp;(مجموعة&nbsp;ريفاميسين)،&nbsp;وهو&nbsp;دواء&nbsp;يستخدم&nbsp;للحماية&nbsp;من&nbsp;رفض&nbsp;الزراعة&nbsp;(سيكلوسبورين)</p><p style="margin-left:0px; margin-right:0px" dir="rtl">أو&nbsp;دواء&nbsp;مضاد&nbsp;للفيروسات&nbsp;القهقرية&nbsp;المستخدمة&nbsp;لعلاج&nbsp;العدوى&nbsp;بفيروس&nbsp;نقص&nbsp;المناعة&nbsp;البشرية&nbsp;/&nbsp;الإيدز&nbsp;(ريتونافير)&nbsp;هذه</p><p style="margin-left:0px; margin-right:0px" dir="rtl">الأدوية&nbsp;قد&nbsp;تزيد&nbsp;من&nbsp;تأثير&nbsp;ديوستار</p><p style="margin-left:0px; margin-right:0px" dir="rtl">ليثيوم،&nbsp;وهو&nbsp;دواء&nbsp;يستخدم&nbsp;لعلاج&nbsp;بعض&nbsp;أنواع&nbsp;الأمراض&nbsp;النفسية</p><p style="margin-left:0px; margin-right:0px">&nbsp;</p><p style="margin-left:0px; margin-right:0px" dir="rtl">بالإضافة&nbsp;إلى&nbsp;ذلك:</p><p style="margin-left:0px; margin-right:0px" dir="rtl">-&nbsp;إذا&nbsp;كنت&nbsp;تخضع&nbsp;للعلاج&nbsp;بعد&nbsp;الإصابة&nbsp;بأزمة&nbsp;قلبية،&nbsp;فمن&nbsp;غير&nbsp;المستحسن&nbsp;الجمع&nbsp;بين&nbsp;ديوستار&nbsp;و&nbsp;مثبطات&nbsp;الإنزيم&nbsp;المحول</p><p style="margin-left:0px; margin-right:0px" dir="rtl">للأنجيوتنسين&nbsp;(ACE) (أدوية&nbsp;لعلاج&nbsp;الأزمة&nbsp;القلبية</p><p style="margin-left:0px; margin-right:0px" dir="rtl">-&nbsp;إذا&nbsp;كنت&nbsp;تخضع&nbsp;لعلاج&nbsp;قصور&nbsp;القلب،&nbsp;فمن&nbsp;غير&nbsp;المستحسن&nbsp;الجمع&nbsp;الثلاثي&nbsp;بين&nbsp;ديوستاره&nbsp;و&nbsp;مثبطات&nbsp;الإنزيم&nbsp;المحول</p><p style="margin-left:0px; margin-right:0px" dir="rtl">للأنجيوتنسين&nbsp;(ACE&nbsp;و&nbsp;حاصرات&nbsp;البيتا&nbsp;(أدوية&nbsp;لعلاج&nbsp;قصور&nbsp;القلب)</p><p style="margin-left:0px; margin-right:0px" dir="rtl">تناول&nbsp;ديوستار&nbsp;أقراص&nbsp;مع&nbsp;الطعام&nbsp;والشراب</p><p style="margin-left:0px; margin-right:0px" dir="rtl">يمكنك&nbsp;استخدام&nbsp;ديوستار&nbsp;أقراص&nbsp;مع&nbsp;أو&nbsp;بدون&nbsp;الطعام</p><p style="margin-left:0px; margin-right:0px" dir="rtl">الحمل&nbsp;والرضاعة&nbsp;الطبيعية</p><p style="margin-left:0px; margin-right:0px" dir="rtl">إسأل&nbsp;طبيبك&nbsp;أو&nbsp;الصيدلي&nbsp;للحصول&nbsp;على&nbsp;المشورة&nbsp;قبل&nbsp;استخدام&nbsp;أي&nbsp;دواء</p><p style="margin-left:0px; margin-right:0px" dir="rtl">-&nbsp;عليك&nbsp;إخبار&nbsp;الطبيب&nbsp;إذا&nbsp;كنت&nbsp;(أو&nbsp;قد&nbsp;تصبحين&nbsp;حامل.&nbsp;طبيبك&nbsp;سوف&nbsp;ينصحك&nbsp;بالتوقف&nbsp;عن&nbsp;تناول&nbsp;ديوستار&nbsp;قبل&nbsp;الحمل</p><p style="margin-left:0px; margin-right:0px" dir="rtl">أو&nbsp;في&nbsp;أقرب&nbsp;وقت&nbsp;تدركين&nbsp;فيه&nbsp;الحمل،&nbsp;وسوف&nbsp;ينصحك&nbsp;باستخدام&nbsp;دواء&nbsp;آخر&nbsp;بدلا&nbsp;من&nbsp;ديوستار&nbsp;لا&nbsp;ينصح&nbsp;باستخدام</p><p style="margin-left:0px; margin-right:0px" dir="rtl">دیوستار&nbsp;في&nbsp;مرحلة&nbsp;مبكرة&nbsp;من&nbsp;الحمل،&nbsp;ولا&nbsp;يستخدم&nbsp;نهائيا&nbsp;إذا&nbsp;كنت&nbsp;حامل&nbsp;أكثر&nbsp;من&nbsp;3&nbsp;أشهر،&nbsp;لأنه&nbsp;قد&nbsp;يسبب&nbsp;ضرر&nbsp;جسيم</p><p style="margin-left:0px; margin-right:0px" dir="rtl">لطفلك&nbsp;إذا&nbsp;تم&nbsp;استخدامه&nbsp;بعد&nbsp;الشهر&nbsp;الثالث&nbsp;من&nbsp;الحمل</p><p style="margin-left:0px; margin-right:0px" dir="rtl">-&nbsp;أخبر&nbsp;طبيبك&nbsp;إذا&nbsp;كنت&nbsp;ترضعين&nbsp;طبيعيا&nbsp;أو&nbsp;على&nbsp;وشك&nbsp;البدء&nbsp;بالرضاعة&nbsp;طبيعية.&nbsp;لا&nbsp;ينصح&nbsp;باستخدام&nbsp;ديوستار&nbsp;للأمهات</p><p style="margin-left:0px; margin-right:0px" dir="rtl">اللواتي&nbsp;يرضعن&nbsp;طبيعيا،&nbsp;وقد&nbsp;ينصحك&nbsp;طبيبك&nbsp;بعلاج&nbsp;آخر&nbsp;إذا&nbsp;كنت&nbsp;ترغبين&nbsp;بالإرضاع&nbsp;طبيعيا،&nbsp;وخاصة&nbsp;إذا&nbsp;كان&nbsp;طفلك</p><p style="margin-left:0px; margin-right:0px" dir="rtl">حديث&nbsp;الولادة،&nbsp;أو&nbsp;ولد&nbsp;قبل&nbsp;الأوان.</p><p style="margin-left:0px; margin-right:0px" dir="rtl">القيادة&nbsp;واستخدام&nbsp;الآلات</p><p style="margin-left:0px; margin-right:0px" dir="rtl">قبل&nbsp;أن&nbsp;تقوم&nbsp;بقيادة&nbsp;المركبات،&nbsp;استخدام&nbsp;الأدوات&nbsp;أو&nbsp;تشغيل&nbsp;الالات،&nbsp;أو&nbsp;القيام&nbsp;بالأنشطة&nbsp;الأخرى&nbsp;التي&nbsp;تتطلب&nbsp;التركيز،</p><p style="margin-left:0px; margin-right:0px" dir="rtl">عليك&nbsp;التأكد&nbsp;من&nbsp;تأثير&nbsp;ديوستار&nbsp;عليك&nbsp;مثل&nbsp;العديد&nbsp;من&nbsp;الأدوية&nbsp;الأخرى&nbsp;المستخدمة&nbsp;لعلاج&nbsp;ارتفاع&nbsp;ضغط&nbsp;الدم،&nbsp;قد&nbsp;يسبب</p><p style="margin-left:0px; margin-right:0px" dir="rtl">ديوستار&nbsp;في&nbsp;حالات&nbsp;نادرة&nbsp;الدوخة&nbsp;ويؤثر&nbsp;على&nbsp;القدرة&nbsp;على&nbsp;التركيز</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">دائما&nbsp;تناول&nbsp;ديوستار&nbsp;أقراص&nbsp;تماما&nbsp;كما&nbsp;أخبرك&nbsp;طبيبك.&nbsp;راجع&nbsp;طبيبك&nbsp;أو&nbsp;الصيدلي&nbsp;إذا&nbsp;كنت&nbsp;غير&nbsp;متأكد بعد&nbsp;الإصابة&nbsp;مؤخرا&nbsp;بأزمة&nbsp;قلبية:&nbsp;بعد&nbsp;الإصابة&nbsp;بالأزمة&nbsp;القلبية&nbsp;يبدأ&nbsp;العلاج&nbsp;عموما&nbsp;في&nbsp;وقت&nbsp;مبكر&nbsp;من&nbsp;بعد&nbsp;12&nbsp;ساعة،&nbsp;و&nbsp;يبدأ</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">عادة&nbsp;بجرعة&nbsp;منخفضة&nbsp;من&nbsp;20&nbsp;ملغم&nbsp;مرتين&nbsp;يوميا.&nbsp;طبيبك&nbsp;سوف&nbsp;يزيد&nbsp;هذه&nbsp;الجرعة&nbsp;تدريجيا&nbsp;على&nbsp;مدى&nbsp;عدة&nbsp;أسابيع&nbsp;إلى&nbsp;حد أقصى&nbsp;و&nbsp;هو&nbsp;160&nbsp;ملغم&nbsp;مرتين&nbsp;يوميا.&nbsp;الجرعة&nbsp;النهائية&nbsp;تعتمد&nbsp;على&nbsp;قدرتك&nbsp;كمريض&nbsp;على&nbsp;استيعاب&nbsp;الجرعة</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">يمكن&nbsp;إعطاء&nbsp;ديوستار&nbsp;جنبا&nbsp;إلى&nbsp;جنب&nbsp;مع&nbsp;علاج&nbsp;آخر&nbsp;للأزمة&nbsp;القلبية،&nbsp;وطبيبك&nbsp;سوف&nbsp;يقرر&nbsp;أي&nbsp;علاج&nbsp;هو&nbsp;مناسب&nbsp;لك.</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">&nbsp;</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">قصور&nbsp;القلب:&nbsp;يبدأ&nbsp;العلاج&nbsp;عموما&nbsp;بجرعة&nbsp;40&nbsp;ملغم&nbsp;مرتين&nbsp;يوميا.&nbsp;طبيبك&nbsp;سوف&nbsp;يزيد&nbsp;الجرعة&nbsp;تدريجيا&nbsp;على&nbsp;مدى&nbsp;عدة</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">أسابيع&nbsp;إلى&nbsp;حد&nbsp;أقصى&nbsp;و&nbsp;هو&nbsp;160&nbsp;ملغم&nbsp;مرتين&nbsp;يوميا.&nbsp;الجرعة&nbsp;النهائية&nbsp;تعتمد&nbsp;على&nbsp;قدرتك&nbsp;كمريض&nbsp;على&nbsp;استيعاب&nbsp;الجرعة</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">يمكن&nbsp;إعطاء&nbsp;ديوستار&nbsp;جنبا&nbsp;إلى&nbsp;جنب&nbsp;مع&nbsp;علاج&nbsp;أخر&nbsp;لقصور&nbsp;القلب،&nbsp;وطبيبك&nbsp;سوف&nbsp;يقرر&nbsp;أي&nbsp;علاج&nbsp;هو&nbsp;مناسب&nbsp;لك</p><p style="margin-left:0cm; margin-right:0cm">&nbsp;</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">ارتفاع&nbsp;ضغط&nbsp;الدم:&nbsp;الجرعة&nbsp;الاعتيادية&nbsp;هي&nbsp;80&nbsp;ملغم&nbsp;يوميا.&nbsp;في&nbsp;بعض&nbsp;الحالات&nbsp;قد&nbsp;يصف&nbsp;الطبيب&nbsp;جرعات&nbsp;أعلى&nbsp;(على</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">سبيل&nbsp;المثال&nbsp;160&nbsp;ملغم&nbsp;أو&nbsp;320&nbsp;ملغم).&nbsp;كما&nbsp;يجوز&nbsp;له&nbsp;الجمع&nbsp;بين&nbsp;ديوستار&nbsp;و&nbsp;دواء&nbsp;إضافي&nbsp;(مثل&nbsp;مدر&nbsp;للبول)</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">يمكنك&nbsp;استخدام&nbsp;ديوستار&nbsp;أقراص&nbsp;مع&nbsp;أو&nbsp;بدون&nbsp;الطعام.&nbsp;ابتلع&nbsp;ديوستار&nbsp;مع&nbsp;كوب&nbsp;من&nbsp;الماء</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">تناول&nbsp;ديوستار&nbsp;في&nbsp;نفس&nbsp;الوقت&nbsp;تقريبا&nbsp;كل&nbsp;يوم.</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">إذا&nbsp;أخذت&nbsp;ديوستار&nbsp;أقراص&nbsp;أكثر&nbsp;مما&nbsp;يجب</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">إذا&nbsp;عانيت&nbsp;من&nbsp;دوخة&nbsp;شديدة&nbsp;و/أو&nbsp;إغماء،&nbsp;استلقي&nbsp;واتصل&nbsp;بطبيبك&nbsp;فورا</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">إذا&nbsp;أخذت&nbsp;عن&nbsp;طريق&nbsp;الخطأ&nbsp;الكثير&nbsp;من&nbsp;الأقراص،&nbsp;راجع&nbsp;طبيبك&nbsp;أو&nbsp;الصيدلي&nbsp;أو&nbsp;قسم&nbsp;الطوارئ&nbsp;في&nbsp;المستشفى&nbsp;فورا.&nbsp;خذ</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">الاقراص&nbsp;المتبقية&nbsp;معك،&nbsp;و&nbsp;علبة&nbsp;الدواء&nbsp;والنشرة&nbsp;و&nbsp;بذلك&nbsp;يسهل&nbsp;التعرف&nbsp;على&nbsp;الأقراص.</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">إذا&nbsp;نسيت&nbsp;أن&nbsp;تأخذ&nbsp;ديوستار&nbsp;أقراص</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">لا&nbsp;تأخذ&nbsp;جرعة&nbsp;مضاعفة&nbsp;لتعويض&nbsp;الجرعة&nbsp;المنسية</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">إذا&nbsp;نسيت&nbsp;تناول&nbsp;الجرعة،&nbsp;تناولها&nbsp;حالما&nbsp;تتذكر&nbsp;ذلك.&nbsp;إذا&nbsp;كان&nbsp;الوقت&nbsp;قريبا&nbsp;لتناول&nbsp;الجرعة&nbsp;التالية،&nbsp;لا&nbsp;تأخذ&nbsp;الجرعة&nbsp;المنسية،</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">وارجع&nbsp;للنظام&nbsp;المعتاد.</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">إذا&nbsp;توقفت&nbsp;عن&nbsp;تناول&nbsp;ديوستار&nbsp;أقراص</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">إيقاف&nbsp;العلاج&nbsp;ب&nbsp;ديوستار&nbsp;قد&nbsp;يؤدي&nbsp;إلى&nbsp;تدهور&nbsp;وضعك&nbsp;الصحي.&nbsp;لا&nbsp;تتوقف&nbsp;عن&nbsp;استخدام&nbsp;الدواء&nbsp;ما&nbsp;لم&nbsp;يخبرك&nbsp;طبيبك&nbsp;بذلك</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">إذا&nbsp;كان&nbsp;لديك&nbsp;أية&nbsp;أسئلة&nbsp;أخرى&nbsp;عن&nbsp;استخدام&nbsp;هذا&nbsp;المنتج،&nbsp;إسأل&nbsp;طبيبك&nbsp;أو&nbsp;الصيدلي</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">مثل&nbsp;باقي&nbsp;الأدوية&nbsp;قد&nbsp;يتسبب&nbsp;فالسارتان&nbsp;أقراص&nbsp;بآثار&nbsp;جانبية،&nbsp;وإن&nbsp;لم&nbsp;يكن&nbsp;الجميع&nbsp;يعاني&nbsp;منها.</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">قد&nbsp;تحدث&nbsp;هذه&nbsp;الآثار&nbsp;الجانبية&nbsp;بتكرار&nbsp;معين،&nbsp;والتي&nbsp;تعرف&nbsp;كما&nbsp;يلي:</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">-&nbsp;شائعة&nbsp;جدا:&nbsp;يؤثر&nbsp;على&nbsp;أكثر&nbsp;من&nbsp;مستخدم&nbsp;من&nbsp;أصل&nbsp;10&nbsp;مستخدمين</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">-&nbsp;شائعة&nbsp;يؤثر&nbsp;على&nbsp;1&nbsp;إلى&nbsp;10&nbsp;مستخدمين&nbsp;من&nbsp;أصل&nbsp;100&nbsp;مستخدم</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">.&nbsp;غير&nbsp;شائعة:&nbsp;يؤثر&nbsp;على&nbsp;1&nbsp;إلى&nbsp;10&nbsp;مستخدمين&nbsp;من&nbsp;أصل&nbsp;1000&nbsp;مستخدم</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">-&nbsp;نادرة:&nbsp;يؤثر&nbsp;على&nbsp;1&nbsp;إلى&nbsp;10&nbsp;مستخدمين&nbsp;من&nbsp;أصل&nbsp;10000&nbsp;مستخدم</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">-&nbsp;نادرة&nbsp;جدا:&nbsp;يؤثر&nbsp;على&nbsp;أقل&nbsp;من&nbsp;1&nbsp;مستخدم&nbsp;من&nbsp;أصل&nbsp;1000&nbsp;مستخدم</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">-&nbsp;غير&nbsp;معروفة:&nbsp;لا&nbsp;يمكن&nbsp;تقدير&nbsp;تكرارها&nbsp;من&nbsp;البيانات&nbsp;المتاحة</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">بعض&nbsp;الأعراض&nbsp;تحتاج&nbsp;إلى&nbsp;عناية&nbsp;طبية&nbsp;فورية:</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">قد&nbsp;تواجه&nbsp;أعراض&nbsp;وذمة&nbsp;وعائية،&nbsp;مثل:</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">-&nbsp;تورم&nbsp;الوجه&nbsp;و&nbsp;اللسان&nbsp;أو&nbsp;الحلق</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">-&nbsp;صعوبة&nbsp;في&nbsp;البلع</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">-&nbsp;الطفح&nbsp;الجلدي&nbsp;العقدي&nbsp;وصعوبات&nbsp;في&nbsp;التنفس</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">إذا&nbsp;عانيت&nbsp;من&nbsp;أي&nbsp;من&nbsp;هذه&nbsp;الأعراض،&nbsp;توقف&nbsp;عن&nbsp;استخدام ديوستار واتصل&nbsp;بطبيبك&nbsp;فورا</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">وتشمل&nbsp;الآثار&nbsp;الجانبية&nbsp;الأخرى:</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">شائعة:</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">-&nbsp;الدوخة&nbsp;والدوار&nbsp;عند&nbsp;الوقوف&nbsp;المفاجي</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">-&nbsp;انخفاض&nbsp;ضغط&nbsp;الدم&nbsp;مع&nbsp;أعراض&nbsp;مثل&nbsp;الدوخة</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">-&nbsp;انخفاض&nbsp;في&nbsp;وظائف&nbsp;الكلى&nbsp;(علامات&nbsp;الفشل&nbsp;الكلوي)</p><p style="margin-left:0cm; margin-right:0cm">&nbsp;</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">غیر&nbsp;شائعة:</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">-&nbsp;رد&nbsp;فعل&nbsp;تحسسي&nbsp;مع&nbsp;أعراض&nbsp;مثل&nbsp;الطفح&nbsp;الجلدي،&nbsp;الحكة،&nbsp;الدوخة،&nbsp;تورم&nbsp;في&nbsp;الوجه&nbsp;أو&nbsp;الشفتين&nbsp;أو&nbsp;اللسان&nbsp;أو&nbsp;الحلق،</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">وصعوبة&nbsp;في&nbsp;التنفس&nbsp;أو&nbsp;البلع&nbsp;(علامات&nbsp;الوذمة&nbsp;الوعائية)</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">-&nbsp;فقدان&nbsp;وعي&nbsp;مفاجئ</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">-&nbsp;الاحساس&nbsp;بالدوار</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">-&nbsp;انخفاض&nbsp;شديد&nbsp;في&nbsp;وظائف&nbsp;الكلى&nbsp;(علامات&nbsp;الفشل&nbsp;الكلوي&nbsp;الحاد)</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">-&nbsp;تشنجات&nbsp;العضلات،&nbsp;ضربات&nbsp;القلب&nbsp;غير&nbsp;طبيعية&nbsp;(علامات&nbsp;فرط&nbsp;البوتاسيوم&nbsp;في&nbsp;الدم)</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">-&nbsp;ضيق&nbsp;التنفس،&nbsp;وصعوبة&nbsp;في&nbsp;التنفس&nbsp;عند&nbsp;الاستلقاء،&nbsp;وتورم&nbsp;في&nbsp;الساقين&nbsp;أو&nbsp;القدمين&nbsp;(علامات&nbsp;قصور&nbsp;القلب)</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">-&nbsp;الصداع</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">-&nbsp;السعال</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">-&nbsp;ألم&nbsp;في&nbsp;البطن</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">.&nbsp;الغثيان</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">-&nbsp;الإسهال</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">-&nbsp;التعب</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">-&nbsp;الضعف&nbsp;العام</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">غير&nbsp;معروفة:</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">-&nbsp;الطفح&nbsp;الجلدي،&nbsp;الحكة،&nbsp;بالتزامن&nbsp;مع&nbsp;بعض&nbsp;العلامات&nbsp;أو&nbsp;الأعراض&nbsp;التالية:&nbsp;ارتفاع&nbsp;درجة&nbsp;الحرارة،&nbsp;آلام&nbsp;المفاصل،&nbsp;آلام</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">العضلات،&nbsp;تضخم&nbsp;الغدد&nbsp;الليمفاوية&nbsp;و&nbsp;/&nbsp;أو&nbsp;أعراض&nbsp;تشبه&nbsp;الأنفلونزا&nbsp;(علامات&nbsp;داء&nbsp;المصل)</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">بقع&nbsp;أرجوانية&nbsp;محمرة،&nbsp;حمی،&nbsp;حكة&nbsp;(علامات&nbsp;التهاب&nbsp;الأوعية&nbsp;الدموية&nbsp;ويسمى&nbsp;التهاب&nbsp;الأوعية&nbsp;الدموية)</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">-&nbsp;نزيف&nbsp;غير&nbsp;عادي&nbsp;أو&nbsp;كدمات&nbsp;(علامات&nbsp;نقص&nbsp;الصفيحات)</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">-&nbsp;آلام&nbsp;في&nbsp;العضلات&nbsp;(ألم&nbsp;عضلي)</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">-&nbsp;حمی،&nbsp;التهاب&nbsp;الحلق&nbsp;أو&nbsp;تقرحات&nbsp;في&nbsp;الفم&nbsp;بسبب&nbsp;الالتهابات&nbsp;(أعراض&nbsp;انخفاض&nbsp;مستوى&nbsp;خلايا&nbsp;الدم&nbsp;البيضاء&nbsp;في&nbsp;الدم</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">أيضا&nbsp;العدلات)</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">-&nbsp;انخفاض&nbsp;مستوى&nbsp;الهيموجلوبين&nbsp;وانخفاض&nbsp;نسبة&nbsp;خلايا&nbsp;الدم&nbsp;الحمراء&nbsp;في&nbsp;الدم&nbsp;(و&nbsp;الذي&nbsp;يمكن،&nbsp;في&nbsp;الحالات&nbsp;الشديدة،&nbsp;أن</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">يؤدي&nbsp;إلى&nbsp;فقر&nbsp;الدم)</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">-&nbsp;زيادة&nbsp;مستوى&nbsp;البوتاسيوم&nbsp;في&nbsp;الدم&nbsp;(والتي&nbsp;يمكن،&nbsp;في&nbsp;الحالات&nbsp;الشديدة،&nbsp;أن&nbsp;تؤدي&nbsp;إلى&nbsp;تشنجات&nbsp;العضلات&nbsp;و&nbsp;اختلال</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">في&nbsp;ضربات&nbsp;القلب)</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">-&nbsp;ارتفاع&nbsp;في&nbsp;قيم&nbsp;تحاليل&nbsp;وظائف&nbsp;الكبد&nbsp;(والذي&nbsp;يمكن&nbsp;أن&nbsp;يشير&nbsp;إلى&nbsp;تلف&nbsp;الكبد)&nbsp;بما&nbsp;في&nbsp;ذلك&nbsp;زيادة&nbsp;البيليروبين&nbsp;في&nbsp;الدم</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">(والذي&nbsp;يمكن،&nbsp;في&nbsp;الحالات&nbsp;الشديدة،&nbsp;أن&nbsp;يؤدي&nbsp;إلى&nbsp;اصفرار&nbsp;البشرة&nbsp;والعيون)</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">-&nbsp;زيادة&nbsp;في&nbsp;مستوى&nbsp;النتروجين&nbsp;اليوريا&nbsp;في&nbsp;الدم&nbsp;وزيادة&nbsp;مستوى&nbsp;الكرياتينين&nbsp;في&nbsp;مصل&nbsp;الدم&nbsp;(والتي&nbsp;يمكن&nbsp;أن&nbsp;تشير&nbsp;إلى</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">اختلال&nbsp;في&nbsp;وظائف&nbsp;الكلى)</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">-&nbsp;انخفاض&nbsp;مستوى&nbsp;الصوديوم&nbsp;في&nbsp;الدم&nbsp;والذي&nbsp;يمكن&nbsp;أن&nbsp;يؤدي&nbsp;إلى&nbsp;التعب،&nbsp;الارتباك،&nbsp;ارتعاش&nbsp;العضلات&nbsp;و&nbsp;/&nbsp;أو&nbsp;تشنجات</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">في&nbsp;الحالات&nbsp;الشديدة)</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">تكرار&nbsp;بعض&nbsp;الآثار&nbsp;الجانبية&nbsp;قد&nbsp;يختلف&nbsp;تبعا&nbsp;لحالتك.&nbsp;على&nbsp;سبيل&nbsp;المثال،&nbsp;الآثار&nbsp;الجانبية&nbsp;مثل&nbsp;الدوخة،&nbsp;وانخفاض&nbsp;وظائف</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">الكلى،&nbsp;تم&nbsp;رصدها&nbsp;عند&nbsp;المرضى&nbsp;الذين&nbsp;يعانون&nbsp;من&nbsp;ارتفاع&nbsp;ضغط&nbsp;الدم&nbsp;أقل&nbsp;بكثير&nbsp;من&nbsp;المرضى&nbsp;الذين&nbsp;يعانون&nbsp;من&nbsp;قصور</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">القلب&nbsp;أو&nbsp;بعد&nbsp;اصابته&nbsp;مؤخرا&nbsp;بأزمة&nbsp;قلبية</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">إذا&nbsp;تطورت&nbsp;أي&nbsp;من&nbsp;الآثار&nbsp;الجانبية&nbsp;لتصبح&nbsp;خطيرة،&nbsp;أو&nbsp;إذا&nbsp;لاحظت&nbsp;أي&nbsp;آثار&nbsp;جانبية&nbsp;غير&nbsp;المذكورة&nbsp;في&nbsp;هذه&nbsp;النشرة،&nbsp;يرجي</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">إخبار&nbsp;طبيبك&nbsp;أو&nbsp;الصيدلي.</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">&nbsp;</p><p style="margin-left:0cm; margin-right:0cm">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">يحفظ&nbsp;بعيدا&nbsp;عن&nbsp;متناول&nbsp;الأطفال&nbsp;و&nbsp;نظرهم.</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">لا&nbsp;تستخدم&nbsp;ديوستار&nbsp;أقراص&nbsp;بعد&nbsp;تاريخ&nbsp;انتهاء&nbsp;الصلاحية&nbsp;(EXP)&nbsp;المذكور&nbsp;على&nbsp;الشريط&nbsp;و&nbsp;العلبة&nbsp;الخارجية</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">تاريخ&nbsp;الانتهاء&nbsp;يشير&nbsp;إلى&nbsp;اليوم&nbsp;الأخير&nbsp;من&nbsp;ذلك&nbsp;الشهر.&nbsp;ديوستار&nbsp;أقراص:&nbsp;يحفظ&nbsp;بدرجة&nbsp;حرارة&nbsp;دون&nbsp;25&nbsp;م</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">يجب&nbsp;أن&nbsp;لا&nbsp;يتم&nbsp;التخلص&nbsp;من&nbsp;الأدوية&nbsp;عن&nbsp;طريق&nbsp;مياه&nbsp;الصرف&nbsp;الصحي&nbsp;أو&nbsp;النفايات&nbsp;المنزلية.&nbsp;اسأل&nbsp;الصيدلي&nbsp;عن&nbsp;كيفية</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">التخلص&nbsp;من&nbsp;الأدوية&nbsp;التي&nbsp;لم&nbsp;تعد&nbsp;مطلوبة.&nbsp;وسوف&nbsp;تساعد&nbsp;هذه&nbsp;التدابير&nbsp;في&nbsp;حماية&nbsp;البيئة</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">المادة&nbsp;الفعالة&nbsp;فالسارتان.</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">المكونات&nbsp;الأخرى&nbsp;هي&nbsp;ميكروکریستالين&nbsp;سيليلوز،&nbsp;کروسکارمیلوز&nbsp;صوديوم،&nbsp;بوفيدون&nbsp;ك،&nbsp;ثنائي&nbsp;أكسيد&nbsp;السيلكون&nbsp;الغروي،</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">مغنيسيوم&nbsp;ستيريت،&nbsp;أوبادري&nbsp;أبيض،&nbsp;لون&nbsp;أحمر&nbsp;FD&amp;c</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">أقراص&nbsp;ديوستار&nbsp;80&nbsp;ملغم&nbsp;المغلفة&nbsp;غشائية:</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">لونها&nbsp;وردي&nbsp;فاتح،&nbsp;دائرية،&nbsp;محفور&nbsp;عليها&nbsp;Phl&nbsp;على&nbsp;أحد&nbsp;الأوجه،&nbsp;وخط&nbsp;يسمح&nbsp;بكسرها&nbsp;لنصفين&nbsp;على&nbsp;الوجه&nbsp;الآخر&nbsp;ومعبأة</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">في&nbsp;شريط&nbsp;من&nbsp;الألومنيوم&nbsp;/&nbsp;الألومنيوم&nbsp;،&nbsp;ومعدة&nbsp;للاستخدام&nbsp;عن&nbsp;طريق&nbsp;الفم.</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">حجم&nbsp;العبوة: 30&nbsp;قرص.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">الشركة&nbsp;الدولية&nbsp;للدواء</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">عمان&nbsp;-&nbsp;الأردن</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">الهاتف:</p><p style="margin-left:0cm; margin-right:0cm">51588905157893-6-00962</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">فاکس: 5154753-6-00962</p><p>البريد&nbsp;الإلكتروني&nbsp;marketing@pic-jo.com</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تم تنقيح النشرة في 12/2014


        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Diostar ® (Valsartan 80mg) F/C tablets
Diostar ® (Valsartan 160mg) F/C tablets


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Diostar ® 80mg F/C tablets: Each film-coated tablet contains 80 mg of valsartan.
Diostar ® 160mg F/C tablets: Each film-coated tablet contains 160 mg of valsartan.

For a full list of excipients, see section 6.1


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film coated tablet.

Diostar® 80mg F/C tablets: are light pink, round film coated tablets, engraved with PhI on one face, and break line on the other Packed in Alu/Alu blisters, intended for oral use.
Diostar® 160mg F/C tablets: pink color, round, normal biconvex film coated tablets, engraved with PhI on one face, packed in Alu/Alu blister, intended for oral use.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Hypertension</u></p><p>Treatment of essential hypertension</p><p><u>Recent myocardial infarction</u></p><p>Treatment of clinically stable patients with symptomatic heart failure or asymptomatic left ventricular systolic dysfunction after a recent (12 hours &ndash; 10 days) myocardial infarction</p><p><u>Heart Failure</u></p><p>Treatment of symptomatic heart failure when Angiotensin Converting Enzyme (ACE) inhibitors cannot be used, or as add-on therapy to ACE inhibitors when beta blockers cannot be used</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em><u>Posology</u></em></p><p><u>Hypertension</u></p><p>The recommended dose of <strong>Diostar<sup>&reg; </sup></strong>is 80 mg once daily<em>. </em>The antihypertensive effect is substantially present within 2 weeks, and maximal effects are attained within 4 weeks. In some patients whose blood pressure is not adequately controlled, the dose can be increased to 160 mg and to a maximum of 320 mg.</p><p><strong>Diostar<sup>&reg;</sup></strong> may also be administered with other antihypertensive agents. The addition of a diuretic such as hydrochlorothiazide will decrease blood pressure even further in these patients.</p><p><u>Recent myocardial infarction</u></p><p>In clinically stable patients, therapy may be initiated as early as 12 hours after a myocardial infarction. After an initial dose of 20 mg twice daily, valsartan should be titrated to 40 mg, 80 mg, and 160 mg twice daily over the next few weeks. The starting dose is provided by the 40 mg divisible tablet.</p><p>The target maximum dose is 160 mg twice daily. In general, it is recommended that patients achieve a dose level of 80 mg twice daily by two weeks after treatment initiation and that the target maximum dose, 160 mg twice daily, be achieved by three months, based on the patient&#39;s tolerability. If symptomatic hypotension or renal dysfunction occur, consideration should be given to a dosage reduction.</p><p>Valsartan may be used in patients treated with other post-myocardial infarction therapies, e.g. thrombolytics, acetylsalicylic acid, beta blockers, statins and diuretics. The combination with ACE inhibitors is not recommended (see sections 4.4 and 5.1).</p><p>Evaluation of post-myocardial infarction patients should always include assessment of renal function.</p><p><u>Heart failure</u></p><p>The recommended starting dose of <strong>Diostar<sup>&reg;</sup></strong> is 40 mg twice daily. Uptitration to 80 mg and 160 mg twice daily should be done at intervals of at least two weeks to the highest dose, as tolerated by the patient. Consideration should be given to reducing the dose of concomitant diuretics. The maximum daily dose administered in clinical trials is 320 mg in divided doses.</p><p>Valsartan may be administered with other heart failure therapies. However, the triple combination of an ACE inhibitor, a beta blocker and valsartan is not recommended (see sections 4.4 and 5.1).</p><p>Evaluation of patients with heart failure should always include assessment of renal function.</p><p><em><u>Method of administration</u></em></p><p><strong>Diostar<sup>&reg;</sup></strong> may be taken independently of a meal and should be administered with water.</p><p><em><u>Additional information on special populations</u></em></p><p><u>Elderly</u></p><p>No dose adjustment is required in elderly patients.</p><p><u>Renal impairment</u></p><p>Use with caution with pre-existing renal insufficiency and severe renal impairment.</p><p><u>Hepatic impairment</u></p><p>In patients with mild to moderate hepatic impairment without cholestasis, the dose of valsartan should not exceed 80mg. <strong>Diostar<sup>&reg;</sup></strong> is contraindicated in patients with severe hepatic impairment and in patients with cholestasis (see sections 4.3, 4.4 and 5.2).</p><p><u>Paediatric patients</u></p><p><strong>Diostar<sup>&reg;</sup></strong> is not recommended for use in children below the age of 18 years due to a lack of data on safety and efficacy.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                - Hypersensitivity to the active substance or to any of the excipients.
- Severe hepatic impairment, biliary cirrhosis and cholestasis.
- Second and third trimester of pregnancy and breastfeeding (see sections 4.4 and 4.6)	
- Diostar® should not be administered with aliskiren in patients with diabetes mellitus or with moderate-to-severe renal impairment (GFR <60 mL/minute/1.73m2).


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Hyperkalaemia</u></p><p>May occur; risk factors include renal dysfunction, diabetes mellitus, concomitant use of potassium-sparing diuretics, potassium supplements, and/or potassium-containing salts. Use with caution with these agents; monitor potassium closely.</p><p><u>Sodium- and/or volume- depleted patients</u></p><p>In severely sodium-depleted and/or volume-depleted patients, such as those receiving high doses of diuretics, symptomatic hypotension may occur in rare cases after initiation of therapy with <strong>Diostar<sup>&reg;</sup></strong>. Sodium and/or volume depletion should be corrected before starting treatment with <strong>Diostar<sup>&reg;</sup></strong>, for example by reducing the diuretic dose.</p><p><u>Hypotension: </u></p><p>During the initiation of therapy, hypotension may occur, particularly in patients with heart failure or post-MI patients. Symptomatic hypotension may occur upon initiation in patients who are salt- or volume-depleted (eg, those treated with high-dose diuretics); correct volume depletion prior to administration. This transient hypotensive response is not a contraindication to further treatment with valsartan.</p><p><u>Renal artery stenosis</u></p><p>Use valsartan with caution in patients with unstinted unilateral/bilateral renal artery stenosis. When unstinted bilateral renal artery stenosis is present, use is generally avoided due to the elevated risk of deterioration in renal function unless possible benefits outweigh risks.</p><p>In patients with bilateral renal artery stenosis or stenosis to a solitary kidney, the safe use of <strong>Diostar<sup>&reg;</sup></strong> has not been established.</p><p>Short-term administration of <strong>Diostar<sup>&reg; </sup></strong>to twelve patients with renovascular hypertension secondary to unilateral renal artery stenosis did not induce any significant changes in renal haemodynamics, serum creatinine, or blood urea nitrogen (BUN). However, other agents that affect the renin-angiotensin system may increase blood urea and serum creatinine in patients with unilateral renal artery stenosis, therefore monitoring of renal function is recommended when patients are treated with valsartan.</p><p><u>Kidney transplantation</u></p><p>There is currently no experience on the safe use of <strong>Diostar<sup>&reg;</sup></strong> in patients who have recently undergone kidney transplantation.</p><p><u>Primary hyperaldosteronism</u></p><p>Patients with primary hyperaldosteronism should not be treated with <strong>Diostar<sup>&reg;</sup></strong>as their renin-angiotensin system is not activated.</p><p><u>Aortic and mitral valve stenosis, obstructive hypertrophic cardiomyopathy</u></p><p>As with all other vasodilators, special caution is indicated in patients suffering from aortic or mitral stenosis, or hypertrophic obstructive cardiomyopathy (HOCM).</p><p><u>Impaired renal function</u></p><p>Renal function deterioration: May be associated with deterioration of renal function and/or increases in serum creatinine, particularly in patients with low renal blood flow (eg, renal artery stenosis, heart failure) whose glomerular filtration rate (GFR) is dependent on efferent arteriolar vasoconstriction by angiotensin II; deterioration may result in oliguria, acute renal failure, and progressive azotemia. Small increases in serum creatinine may occur following initiation; consider discontinuation only in patients with progressive and/or significant deterioration in renal function.</p><p>No dosage adjustment is required for patients with a creatinine clearance &gt;10 ml/min. There is currently no experience on the safe use in patients with a creatinine clearance &lt;10 ml/min and patients undergoing dialysis, therefore valsartan should be used with caution in these patients (see sections 4.2 and 5.2).</p><p><u>Hepatic impairment</u></p><p>Use caution in patients with significant hepatic impairment since clearance is significantly reduced.</p><p>&nbsp;(See sections 4.2 and 5.2).</p><p><u>Pregnancy</u></p><p><strong><u>Pregnancy category D</u></strong></p><p>Angiotensin II Receptor Antagonists (AIIRAs) should not be initiated during pregnancy. Unless continued AIIRAs therapy is considered essential, patients planning pregnancy should be changed to alternative anti-hypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with AIIRAs should be stopped immediately, and, if appropriate, alternative therapy should be started (see sections 4.3 and 4.6).</p><p><u>Recent myocardial infarction</u></p><p>The combination of captopril and valsartan has shown no additional clinical benefit, instead the risk for adverse events increased compared to treatment with the respective therapies (see sections 4.2 and 5.1). Therefore, the combination of valsartan with an ACE inhibitor is not recommended.</p><p>Caution should be observed when initiating therapy in post-myocardial infarction patients. Evaluation of post-myocardial infarction patients should always include assessment of renal function (see section 4.2).</p><p>Use of <strong>Diostar<sup>&reg; </sup></strong>in post-myocardial infarction patients commonly results in some reduction in blood pressure, but discontinuation of therapy because of continuing symptomatic hypotension is not usually necessary provided dosing instructions are followed (see section 4.2).</p><p><u>Heart Failure</u></p><p>In patients with heart failure, the triple combination of an ACE inhibitor, a beta blocker and <strong>Diostar<sup>&reg; </sup></strong>has not shown any clinical benefit (see section 5.1). This combination apparently increases the risk for adverse events and is therefore not recommended.</p><p>Use caution when initiating in heart failure; may need to adjust dose, and/or concurrent diuretic therapy, because of valsartan-induced hypotension. Careful monitoring of BUN, serum creatinine, and potassium is necessary especially if pre-existing renal disease exists. (see section 4.2).</p><p>Use of <strong>Diostar<sup>&reg; </sup></strong>in patients with heart failure commonly results in some reduction in blood pressure, but discontinuation of therapy because of continuing symptomatic hypotension is not usually necessary provided dosing instructions are followed (see section 4.2).</p><p>In patients whose renal function may depend on the activity of the renin-angiotensin system (e.g. patients with severe congestive heart failure), treatment with angiotensin converting enzyme inhibitors has been associated with oliguria and/or progressive azotaemia and in rare cases with acute renal failure and/or death. As valsartan is an angiotensin II antagonist, it cannot be excluded that the use of <strong>Diostar<sup>&reg; </sup></strong>may be associated with impairment of the renal function.</p><p><u>History of angioedema</u></p><p>Angioedema has been reported rarely with some angiotensin II receptor antagonists (ARBs) and may occur at any time during treatment (especially following first dose). It may involve the head and neck (potentially compromising airway) or the intestine (presenting with abdominal pain). Patients with idiopathic or hereditary angioedema or previous angioedema associated with ACE-inhibitor therapy may be at an increased risk. Prolonged frequent monitoring may be required, especially if tongue, glottis, or larynx are involved, as they are associated with airway obstruction. Patients with a history of airway surgery may have a higher risk of airway obstruction. Discontinue therapy immediately if angioedema occurs. Aggressive early management is critical. Intramuscular (I.M.) administration of epinephrine may be necessary. Do not readminister to patients who have had angioedema with ARBs. (see section 4.8).</p><p><u>Dual blockade of the renin-angiotensin-aldesterone system (RAAS)</u></p><p>Combination therapy of ACE inhibitors (Angiotensin converting enzyme inhibitors) and ARB (Angiotensin receptors blockers) drugs may cause an increased risk of hyperkalemia, worsening of the kidney function and hypotension. Therefore, this combination should not be used, especially in patients with kidney problems.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em><u>Concomitant use not recommended</u></em></p><p><em>Lithium</em></p><p>Reversible increases in serum lithium concentrations and toxicity have been reported during concurrent use of ACE inhibitors. Due to the lack of experience with concomitant use of valsartan and lithium, this combination is not recommended. If the combination proves necessary, careful monitoring of serum lithium levels is recommended.</p><p><em>Potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium and other substances that may increase potassium levels</em></p><p>If a medicinal product that affects potassium levels is considered necessary in combination with valsartan, monitoring of potassium plasma levels is advised.</p><p><em><u>Caution required with concomitant use</u></em></p><p><em>Non-steroidal anti-inflammatory medicines (NSAIDs), including selective COX-2 inhibitors, acetylsalicylic acid &gt;3 g/day), and non-selective NSAIDs</em></p><p>When angiotensin II antagonists are administered simultaneously with NSAIDs, attenuation of the antihypertensive effect may occur. Furthermore, concomitant use of angiotensin II antagonists and NSAIDs may lead to an increased risk of worsening of renal function and an increase in serum potassium. Therefore, monitoring of renal function at the beginning of the treatment is recommended, as well as adequate hydration of the patient.</p><p><em>Transporters</em></p><p>In vitro data indicates that valsartan is a substrate of the hepatic uptake transporter OATP1B1/OATP1B3 and the hepatic efflux transporter MRP2. The clinical relevance of this finding is unknown. Co-administration of inhibitors of the uptake transporter (eg. rifampin, ciclosporin) or efflux transporter (eg. ritonavir) may increase the systemic exposure to valsartan. Exercise appropriate care when initiating or ending concomitant treatment with such drugs.</p><p><em><u>Dual (RAAS) blockade</u></em></p><p>The combination of aliskiren with ARBs or ACE inhibitors is contraindicated in patients with diabetes mellitus or renal impairment.</p><p>Dual blockade (e.g. by adding an ACE inhibitor to an angiotensin II receptor antagonist) should not be used, especially in patients with kidney problems.</p><p><em>Others</em></p><p>ACE Inhibitors: Angiotensin II Receptor Blockers may enhance the adverse/toxic effect of ACE Inhibitors. Angiotensin II Receptor Blockers may increase the serum concentration of ACE Inhibitors. Management: Concurrent use of telmisartan and ramipril is specifically not recommended. It is not clear if any other combination of an ACE inhibitor and an ARB would be any safer. Consider alternatives to the combination when possible.<em>Risk D: Consider therapy modification</em></p><p>Alfuzosin: May enhance the hypotensive effect of Antihypertensives.<em>&nbsp;Risk C: Monitor therapy</em></p><p>Aliskiren: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers. Aliskiren may enhance the hypotensive effect of Angiotensin II Receptor Blockers. Aliskiren may enhance the nephrotoxic effect of Angiotensin II Receptor Blockers. Management: Avoid aliskiren use with ACEIs or ARBs in patients with diabetes or estimated glomerular filtration rate below 60 mL/min. In other patients receiving these combinations, monitor serum potassium, serum creatinine, and blood pressure periodically.<em>&nbsp;Risk D: Consider therapy modification</em></p><p>Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine. Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.<em>&nbsp;Risk D: Consider therapy modification</em></p><p>Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.<em>&nbsp;Risk C: Monitor therapy</em></p><p>Barbiturates: May enhance the hypotensive effect of Hypotensive Agents.<em>&nbsp;Risk C: Monitor therapy</em></p><p>Brimonidine (Topical): May enhance the antihypertensive effect of Antihypertensives.<em>&nbsp;Risk C: Monitor therapy</em></p><p>Canagliflozin: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers. Canagliflozin may enhance the hypotensive effect of Angiotensin II Receptor Blockers.<em>&nbsp;Risk C: Monitor therapy</em></p><p>CycloSPORINE (Systemic): Angiotensin II Receptor Blockers may enhance the hyperkalemic effect of CycloSPORINE (Systemic).&nbsp;<em>Risk C: Monitor therapy</em></p><p>Diazoxide: May enhance the hypotensive effect of Antihypertensives.<em>&nbsp;Risk C: Monitor therapy</em></p><p>DULoxetine: Hypotensive Agents may enhance the orthostatic hypotensive effect of DULoxetine.&nbsp;<em>Risk C: Monitor therapy</em></p><p>Eltrombopag: May increase the serum concentration of OATP1B1/SLCO1B1 Substrates. Management: According to eltrombopag prescribing information, consideration of a preventative dose reduction may be warranted.<em>&nbsp;Risk D: Consider therapy modification</em></p><p>Eplerenone: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.<em>&nbsp;Risk C: Monitor therapy</em></p><p>Heparin: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.<em>&nbsp;Risk C: Monitor therapy</em></p><p>Heparin (Low Molecular Weight): May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.<em>&nbsp;Risk C: Monitor therapy</em></p><p>Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.<em>&nbsp;Risk C: Monitor therapy</em></p><p>Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.<em>&nbsp;Risk C: Monitor therapy</em></p><p>Hydrochlorothiazide: May enhance the hypotensive effect of Valsartan. Valsartan may increase the serum concentration of Hydrochlorothiazide.<em>&nbsp;Risk C: Monitor therapy</em></p><p>Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.<em>&nbsp;Risk C: Monitor therapy</em></p><p>Levodopa: Hypotensive Agents may enhance the orthostatic hypotensive effect of Levodopa.&nbsp;<em>Risk C: Monitor therapy</em></p><p>Lithium: Angiotensin II Receptor Blockers may increase the serum concentration of Lithium. Management: Lithium dosage reductions will likely be needed following the addition of an angiotensin II receptor antagonist.<em>&nbsp;Risk D: Consider therapy modification</em></p><p>MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.<strong>&nbsp;Exceptions:&nbsp;</strong>Linezolid; Tedizolid.<em>&nbsp;Risk C: Monitor therapy</em></p><p>MAO Inhibitors: May enhance the hypotensive effect of Antihypertensives. MAO Inhibitors may enhance the orthostatic hypotensive effect of Antihypertensives.<strong>&nbsp;Exceptions:&nbsp;</strong>Linezolid; Tedizolid.<em>&nbsp;Risk C: Monitor therapy</em></p><p>Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.<em>&nbsp;Risk C: Monitor therapy</em></p><p>Nonsteroidal Anti-Inflammatory Agents: Angiotensin II Receptor Blockers may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Angiotensin II Receptor Blockers. The combination of these two agents may also significantly decrease glomerular filtration and renal function.&nbsp;<em>Risk C: Monitor therapy</em></p><p>Obinutuzumab: Antihypertensives may enhance the hypotensive effect of Obinutuzumab. Management: Consider temporarily withholding antihypertensive medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<em>&nbsp;Risk D: Consider therapy modification</em></p><p>Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.<em>&nbsp;Risk C: Monitor therapy</em></p><p>Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.<em>&nbsp;Risk C: Monitor therapy</em></p><p>Potassium Salts: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.<em>&nbsp;Risk C: Monitor therapy</em></p><p>Potassium-Sparing Diuretics: Angiotensin II Receptor Blockers may enhance the hyperkalemic effect of Potassium-Sparing Diuretics.&nbsp;<em>Risk C: Monitor therapy</em></p><p>Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.<em>&nbsp;Risk C: Monitor therapy</em></p><p>RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.&nbsp;<em>Risk D: Consider therapy modification</em></p><p>Sodium Phosphates: Angiotensin II Receptor Blockers may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced. Management: Consider avoiding this combination by temporarily suspending treatment with ARBs, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, maintain adequate hydration and monitor renal function closely.<em>&nbsp;Risk D: Consider therapy modification</em></p><p>Tolvaptan: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.<em>&nbsp;Risk C: Monitor therapy</em></p><p>Trimethoprim: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.<em>&nbsp;Risk C: Monitor therapy</em></p><p>Yohimbine: May diminish the antihypertensive effect of Antihypertensives.<em>&nbsp;Risk C: Monitor therapy</em></p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em><u>Pregnancy (pregnancy category D)</u></em></p><p>&nbsp;</p><p>The use of Angiotensin II Receptor Antagonists (AIIRAs) is not recommended during the first trimester of pregnancy (see section 4.4). The use of AIIRAs is contra-indicated during the second and third trimester of pregnancy (see sections 4.3 and 4.4).</p><p>&nbsp;</p><p>Epidemiological evidence regarding the risk of teratogenicity following exposure to ACE inhibitors during the first trimester of pregnancy has not been conclusive; however, a small increase in risk cannot be excluded. Whilst there is no controlled epidemiological data on the risk with AIIRAs, similar risks may exist for this class of drugs. Unless continued AIIRA therapy is considered essential, patients planning pregnancy should be changed to alternative anti-hypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with AIIRAs should be stopped immediately, and, if appropriate, alternative therapy should be started.</p><p>AIIRAs therapy exposure during the second and third trimesters is known to induce human fetotoxicity (decreased renal function, oligohydramnios, skull ossification retardation) and neonatal toxicity (renal failure, hypotension, hyperkalemia); see also section 5.3 &ldquo;Preclinical safety data&rdquo;.</p><p>Should exposure to AIIRAs have occurred from the second trimester of pregnancy, ultrasound check of renal function and skull is recommended.</p><p>Infants whose mothers have taken AIIRAs should be closely observed for hypotension (see also sections 4.3 and 4.4).</p><p><em><u>Lactation</u></em></p><p>Because no information is available regarding the use of valsartan during breastfeeding, <strong>Diostar<sup>&reg; </sup></strong>is not recommended and alternative treatments with better established safety profiles during breast-feeding are preferable, especially while nursing a newborn or preterm infant.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:11pt; margin-right:18.4pt; text-align:left">No studies on the effects on the ability to drive have been performed. When driving vehicles or operating machines it should be taken into account that occasionally dizziness or weariness may occur.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In controlled clinical studies in patients with hypertension, the overall incidence of adverse reactions (ADRs) was comparable with placebo and is consistent with the pharmacology of valsartan. The incidence of ADRs did not appear to be related to dose or treatment duration and also showed no association with gender, age or race.</p><p>The ADRs reported from clinical studies, post-marketing experience and laboratory findings are listed below according to system organ class.</p><p>Adverse reactions are ranked by frequency, the most frequent first, using the following convention: very common (&ge;1/10); common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1000 to &lt;1/100); rare (&ge;1/10,000 to &lt;1/1000); very rare (&lt;1/10, 000), including isolated reports. Within each frequency grouping, adverse reactions are ranked in order of decreasing seriousness.</p><p>For all the ADRs reported from post-marketing experience and laboratory findings, it is not possible to apply any ADR frequency and therefore they are mentioned with a &quot;not known&quot; frequency.</p><p>&bull;<strong> Hypertension</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:0px"><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong>Blood and lymphatic system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Decrease in haemoglobin, Decrease in haematocrit, Neutropenia, Thrombocytopenia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Immune system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Hypersensitivity including serum sickness</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Increase of serum potassium, hyponatraemia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Ear and labyrinth system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Vertigo</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Vascular disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Vasculitis</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Cough</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Abdominal pain</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Hepato-biliary Disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Elevation of liver function values including increase of serum bilirubin.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Angioedema, Rash, Pruritus</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Myalgia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Renal and urinary disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Renal failure and impairment, Elevation of serum creatinine</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Fatigue</p></td></tr></tbody></table><p>The safety profile seen in controlled-clinical studies in patients with post-myocardial infarction and/or heart failure varies from the overall safety profile seen in hypertensive patients. This may relate to the patients underlying disease. ADRs that occurred in post-myocardial infarction and/or heart failure patients are listed below:</p><p>&bull;<strong> Post-myocardial infarction and/or heart failure</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:0px"><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong>Blood and lymphatic system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Thrombocytopenia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Immune system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Hypersensitivity including serum sickness</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Hyperkalaemia</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Increase of serum potassium, hyponatraemia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Dizziness, Postural dizziness</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Syncope, Headache</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Ear and labyrinth system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Vertigo</p></td></tr><tr><td style="vertical-align:top"><p><strong>Cardiac disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Cardiac failure</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Vascular disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Hypotension, Orthostatic hypotension</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Vasculitis</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Cough</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Nausea, Diarrhoea</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Hepatobiliary Disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Elevation of liver function values</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Angioedema</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Rash, Pruritus</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Myalgia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Renal and urinary disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Renal failure and impairment</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Acute renal failure, Elevation of serum creatinine</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Increase in Blood Urea Nitrogen</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Asthenia, Fatigue</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>To report any side effect(s):</strong></p><p><strong>&bull;Saudi Arabia:</strong></p><p>The National Pharmacovigilance Center (NPC):</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p><p><strong>&bull;United Arab of Emirates:</strong></p><p>Pharmacovigilance and Medical Device Section</p><p>P.O. Box: 1853, Tel: 80011111</p><p>Email: pv@mohap.gov.ae</p><p>Drug Department, Ministry of Health &amp; Prevention</p><p>Dubai-UAE.</p><p><strong>&bull;Other GCC States:</strong></p><p>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Symptoms</u></p><p>Overdose with <strong>Diostar<sup>&reg; </sup></strong>may result in marked hypotension, which could lead to depressed levels of consciousness, circulatory collapse and/or shock.</p><p><u>Treatment</u></p><p>The therapeutic measures depend on the time of ingestion and the type and severity of the symptoms; stabilisation of the circulatory condition is of prime importance.</p><p>If hypotension occurs, the patient should be placed in a supine position and blood volume correction should be undertaken.</p><p>Valsartan is unlikely to be removed by haemodialysis.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic groups: Angiotensin II Antagonists, plain ATC code: C09CA03.</p><p>Valsartan is an orally active, potent, and specific angiotensin II (Ang II) receptor antagonist. It acts selectively on the AT<sub>1</sub> receptor subtype, which is responsible for the known actions of angiotensin II. The increased plasma levels of Ang II following AT<sub>1</sub> receptor blockade with valsartan may stimulate the unblocked AT<sub>2</sub> receptor, which appears to counterbalance the effect of the AT<sub>1</sub> receptor. Valsartan does not exhibit any partial agonist activity at the AT<sub>1</sub> receptor and has much (about 20,000 fold) greater affinity for the AT<sub>1</sub> receptor than for the AT<sub>2</sub> receptor. Valsartan is not known to bind to or block other hormone receptors or ion channels known to be important in cardiovascular regulation.</p><p>Valsartan does not inhibit ACE (also known as kininase II), which converts Ang I to Ang II and degrades bradykinin. Since there is no effect on ACE and no potentiation of bradykinin or substance P, angiotensin II antagonists are unlikely to be associated with coughing. In clinical trials where valsartan was compared with an ACE inhibitor, the incidence of dry cough was significantly (P &lt; 0.05) less in patients treated with valsartan than in those treated with an ACE inhibitor (2.6 % versus 7.9 % respectively). In a clinical trial of patients with a history of dry cough during ACE inhibitor therapy, 19.5 % of trial subjects receiving valsartan and 19.0 % of those receiving a thiazide diuretic experienced cough compared to 68.5 % of those treated with an ACE inhibitor (P &lt; 0.05).</p><p><u>Hypertension</u></p><p>Administration of <strong>Diostar<sup>&reg; </sup></strong>to patients with hypertension results in reduction of blood pressure without affecting pulse rate.</p><p>In most patients, after administration of a single oral dose, onset of antihypertensive activity occurs within 2 hours, and the peak reduction of blood pressure is achieved within 4-6 hours. The antihypertensive effect persists over 24 hours after dosing. During repeated dosing, the antihypertensive effect is substantially present within 2 weeks, and maximal effects are attained within 4 weeks and persist during long-term therapy. Combined with hydrochlorothiazide, a significant additional reduction in blood pressure is achieved.</p><p>Abrupt withdrawal of <strong>Diostar<sup>&reg; </sup></strong>has not been associated with rebound hypertension or other adverse clinical events.</p><p>In hypertensive patients with type 2 diabetes and microalbuminuria, valsartan has been shown to reduce the urinary excretion of albumin. The MARVAL (Micro Albuminuria Reduction with Valsartan) study assessed the reduction in urinary albumin excretion (UAE) with valsartan (80-160 mg/od) versus amlodipine (5-10 mg/od), in 332 type 2 diabetic patients (mean age: 58 years; 265 men) with microalbuminuria (valsartan: 58 &micro;g/min; amlodipine: 55.4 &micro;g/min), normal or high blood pressure and with preserved renal function (blood creatinine &lt;120 &micro;mol/l). At 24 weeks, UAE was reduced (p&lt;0.001) by 42% (&ndash;24.2 &micro;g/min; 95% CI: &ndash;40.4 to &ndash;19.1) with valsartan and approximately 3% (&ndash;1.7 &micro;g/min; 95% CI: &ndash;5.6 to 14.9) with amlodipine despite similar rates of blood pressure reduction in both groups.</p><p>The <strong>Diostar<sup>&reg; </sup></strong>Reduction of Proteinuria (DROP) study further examined the efficacy of valsartan in reducing UAE in 391 hypertensive patients (BP=150/88 mmHg) with type 2 diabetes, albuminuria (mean=102 &micro;g/min; 20-700 &micro;g/min) and preserved renal function (mean serum creatinine = 80 &micro;mol/l). Patients were randomized to one of 3 doses of valsartan (160, 320 and 640 mg/od) and treated for 30 weeks. The purpose of the study was to determine the optimal dose of valsartan for reducing UAE in hypertensive patients with type 2 diabetes. At 30 weeks, the percentage change in UAE was significantly reduced by 36% from baseline with valsartan 160 mg (95%CI: 22 to 47%), and by 44% with valsartan 320 mg (95%CI: 31 to 54%). It was concluded that 160-320 mg of valsartan produced clinically relevant reductions in UAE in hypertensive patients with type 2 diabetes.</p><p><u>Recent myocardial infarction</u></p><p>The VALsartan In Acute myocardial iNfarcTion trial (VALIANT) was a randomised, controlled, multinational, double-blind study in 14,703 patients with acute myocardial infarction and signs, symptoms or radiological evidence of congestive heart failure and/or evidence of left ventricular systolic dysfunction (manifested as an ejection fraction &le; 40% by radionuclide ventriculography or &le; 35% by echocardiography or ventricular contrast angiography). Patients were randomized within 12 hours to 10 days after the onset of myocardial infarction symptoms to valsartan, captopril, or the combination of both. The mean treatment duration was two years. The primary endpoint was time to all-cause mortality.</p><p>Valsartan was as effective as captopril in reducing all-cause mortality after myocardial infarction. All-cause mortality was similar in the valsartan (19.9 %), captopril (19.5 %), and valsartan+captopril (19.3 %) groups. Combining valsartan with captopril did not add further benefit over captopril alone. There was no difference between valsartan and captopril in all-cause mortality based on age, gender, race, baseline therapies or underlying disease. Valsartan was also effective in prolonging the time to and reducing cardiovascular mortality, hospitalisation for heart failure, and recurrent myocardial infarction, resuscitated cardiac arrest, and non-fatal stroke (secondary composite endpoint.)</p><p>The safety profile of valsartan was consistent with the clinical course of patients treated in the post-myocardial infarction setting. Regarding renal function, doubling of serum creatinine was observed in 4.2% of valsartan-treated patients, 4.8% of valsartan+captopril-treated patients, and 3.4% of captopril-treated patients. Discontinuations due to various types of renal dysfunction occurred in 1.1% of valsartan-treated patients, 1.3% in valsartan+captopril patients, and 0.8% of captopril patients. An assessment of renal function should be included in the evaluation of patients post-myocardial infarction.</p><p>There was no difference in all-cause mortality or cardiovascular mortality or morbidity when beta-blockers were administered together with the combination of valsartan + captopril, valsartan alone, or captopril alone. Irrespective of treatment, mortality was lower in the group of patients treated with a beta blocker, suggesting that the known beta blocker benefit in this population was maintained in this trial.</p><p><u>Heart failure</u></p><p>Val-HeFT was a randomised, controlled, multinational clinical trial of valsartan compared with placebo on morbidity and mortality in 5,010 NYHA class II (62%), III (36%) and IV (2%) heart failure patients receiving usual therapy with LVEF &lt;40% and left ventricular internal diastolic diameter (LVIDD) &gt;2.9 cm/m<sup>2</sup>. Baseline therapy included ACE inhibitors (93%), diuretics (86%), digoxin (67%) and beta blockers (36%). The mean duration of follow-up was nearly two years. The mean daily dose of <strong>Diostar<sup>&reg; </sup></strong>in Val-HeFT was 254 mg. The study had two primary endpoints: all cause mortality (time to death) and composite mortality and heart failure morbidity (time to first morbid event) defined as death, sudden death with resuscitation, hospitalisation for heart failure, or administration of intravenous inotropic or vasodilator agents for four hours or more without hospitalisation.</p><p>All cause mortality was similar (p=NS) in the valsartan (19.7%) and placebo (19.4%) groups. The primary benefit was a 27.5% (95% CI: 17 to 37%) reduction in risk for time to first heart failure hospitalisation (13.9% vs. 18.5%). Results appearing to favour placebo (composite mortality and morbidity was 21.9% in placebo vs. 25.4% in valsartan group) were observed for those patients receiving the triple combination of an ACE inhibitor, a beta blocker and valsartan.</p><p>In a subgroup of patients not receiving an ACE inhibitor (n=366), the morbidity benefits were greatest. In this subgroup all-cause mortality was significantly reduced with valsartan compared to placebo by 33% (95% CI: &ndash;6% to 58%) (17.3% valsartan vs. 27.1% placebo) and the composite mortality and morbidity risk was significantly reduced by 44% (24.9% valsartan vs. 42.5% placebo).</p><p>In patients receiving an ACE inhibitor without a beta-blocker, all cause mortality was similar (p=NS) in the valsartan (21.8%) and placebo (22.5%) groups. Composite mortality and morbidity risk was significantly reduced by 18.3% (95% CI: 8% to 28%) with valsartan compared with placebo (31.0% vs. 36.3%).</p><p>In the overall Val-HeFT population, valsartan treated patients showed significant improvement in NYHA class, and heart failure signs and symptoms, including dyspnoea, fatigue, oedema and rales compared to placebo. Patients treated with valsartan had a better quality of life as demonstrated by change in the Minnesota Living with Heart Failure Quality of Life score from baseline at endpoint than placebo. Ejection fraction in valsartan treated patients was significantly increased and LVIDD significantly reduced from baseline at endpoint compared to placebo.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em><u>Absorption:</u></em></p><p>Following oral administration of valsartan alone, peak plasma concentrations of valsartan are reached in 2&ndash;4 hours. Mean absolute bioavailability is 23%. Food decreases exposure (as measured by AUC) to valsartan by about 40% and peak plasma concentration (C<sub>max</sub>) by about 50%, although from about 8 h post dosing plasma valsartan concentrations are similar for the fed and fasted groups. This reduction in AUC is not, however, accompanied by a clinically significant reduction in the therapeutic effect. Food decreases the peak plasma concentration and extent of absorption by 50% and 40%, respectively. Management: Administer consistently with regard to food.</p><p><em><u>Distribution:</u></em></p><p>The steady-state volume of distribution of valsartan after intravenous administration is about 17 litres, indicating that valsartan does not distribute into tissues extensively. Valsartan is highly bound to serum proteins (94&ndash;97%), mainly serum albumin.</p><p><em><u>Biotransformation:</u></em></p><p>Valsartan is not biotransformed to a high extent as only about 20% of dose is recovered as metabolites. A hydroxy metabolite has been identified in plasma at low concentrations (less than 10% of the valsartan AUC). This metabolite is pharmacologically inactive.</p><p><em><u>Excretion:</u></em></p><p>Valsartan shows multiexponential decay kinetics (t<sub>&frac12;&alpha;</sub> &lt;1 h and t<sub>&frac12;&szlig;</sub> about 9 h). Valsartan is primarily eliminated by biliary excretion in faeces (about 83% of dose) and renally in urine (about 13% of dose), mainly as unchanged drug. Following intravenous administration, plasma clearance of valsartan is about 2 l/h and its renal clearance is 0.62 l/h (about 30% of total clearance). The half-life of valsartan is 6 hours.</p><p><u>In Heart failure patients: </u></p><p>The average time to peak concentration and elimination half-life of valsartan in heart failure patients are similar to that observed in healthy volunteers. AUC and C<sub>max</sub> values of valsartan are almost proportional with increasing dose over the clinical dosing range (40 to 160 mg twice a day). The average accumulation factor is about 1.7. The apparent clearance of valsartan following oral administration is approximately 4.5 l/h. Age does not affect the apparent clearance in heart failure patients.</p><p><em><u>Special populations</u></em></p><p><u>Elderly</u></p><p>A somewhat higher systemic exposure to valsartan was observed in some elderly subjects than in young subjects; however, this has not been shown to have any clinical significance..</p><p><u>Impaired renal function</u></p><p>As expected for a compound where renal clearance accounts for only 30% of total plasma clearance, no correlation was seen between renal function and systemic exposure to valsartan. Dose adjustment is therefore not required in patients with renal impairment (creatinine clearance &gt;10 ml/min). There is currently no experience on the safe use in patients with a creatinine clearance &lt;10 ml/min and patients undergoing dialysis, therefore valsartan should be used with caution in these patients (see sections 4.2 and 4.4). Valsartan is highly bound to plasma protein and is unlikely to be removed by dialysis.</p><p><u>Hepatic impairment</u></p><p>Approximately 70% of the dose absorbed is eliminated in the bile, essentially in the unchanged form. Valsartan does not undergo any noteworthy biotransformation. A doubling of exposure (AUC) was observed in patients with mild to moderate hepatic impairment compared to healthy subjects. However, no correlation was observed between plasma valsartan cocentration versus degree of hepatic dysfunction. <strong>Diostar<sup>&reg; </sup></strong>has not been studied in patients with severe hepatic dysfunction (see sections 4.2, 4.3 and 4.4).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential.</p><p>In rats, maternally toxic doses (600 mg/kg/day) during the last days of gestation and lactation led to lower survival, lower weight gain and delayed development (pinna detachment and ear-canal opening) in the offspring (see section 4.6). These doses in rats (600 mg/kg/day) are approximately 18 times the maximum recommended human dose on a mg/m<sup>2</sup> basis (calculations assume an oral dose of 320 mg/day and a 60-kg patient).</p><p>In non-clinical safety studies, high doses of valsartan (200 to 600 mg/kg body weight) caused in rats a reduction of red blood cell parameters (erythrocytes, haemoglobin, haematocrit) and evidence of changes in renal haemodynamics (slightly raised plasma urea, and renal tubular hyperplasia and basophilia in males). These doses in rats (200 and 600 mg/kg/day) are approximately 6 and 18 times the maximum recommended human dose on a mg/m<sup>2</sup> basis (calculations assume an oral dose of 320 mg/day and a 60-kg patient).</p><p>In marmosets at similar doses, the changes were similar though more severe, particularly in the kidney where the changes developed to a nephropathy which included raised urea and creatinine.</p><p>Hypertrophy of the renal juxtaglomerular cells was also seen in both species. All changes were considered to be caused by the pharmacological action of valsartan which produces prolonged hypotension, particularly in marmosets. For therapeutic doses of valsartan in humans, the hypertrophy of the renal juxtaglomerular cells does not seem to have any relevance.</p><p>6. Pharmaceutical particulars</p><table border="0" cellpadding="0"><tbody><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Microcrystalline cellulose, croscarmellose sodium, Povidone K, colloidal silicon dioxide, magnesium stearate, Opadry OY-L White, FD&amp;C red.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:14.35pt; margin-right:425.3pt; text-align:left; text-indent:-3.4pt">Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                36 months.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C.</p><p>Store in the original package in order to protect from moisture</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Diostar<sup>&reg;</sup></strong> 80mg F/C tablets: are light pink, round film coated tablets, engraved with PhI on one face, and break line on the other Packed in Alu/Alu blisters, intended for oral use.</p><p><strong>Pack size:</strong> 30 tablets</p><p><strong>Diostar<sup>&reg;</sup></strong> 160mg F/C tablets: pink color, round, normal biconvex film coated tablets, engraved with PhI on one face, packed in Alu/Alu blister, intended for oral use.</p><p><strong>Pack size:</strong> 30 tablets</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Pharma International Company
Amman - Jordan
Tel: 00962-6-5158890 / 5157893 
Fax: 00962-6-5154753
email: marketing@pic-jo.com

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                01/2024
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>